


# EXHIBIT 1

Case No. 21-214-CS-S

Marcia Clevesy, APRN

Marcia Clevesy  
1950 Pinto Lane  
Las Vegas, NV 89106  
21-214-CS-S NIAA / Cease and Desist



9171 9690 0935 0265 1323 38





Track Another Package +

Tracking Number: 9171969009350265132338

Remove X

Your item was delivered to an individual at the address at 2:30 pm on January 31, 2022 in LAS VEGAS, NV 89106.

USPS Tracking Plus™ Available ✓

✓ Delivered, Left with Individual

January 31, 2022 at 2:30 pm  
LAS VEGAS, NV 89106

Feedback

Get Updates ✓

Text & Email Updates	✓
Tracking History	✓
USPS Tracking Plus™	✓
Product Information	✓

See Less ^

**COMPLETE THIS SECTION ON DELIVERY**

- Complete items 1, 2, and 3.
- Print your name and address on the reverse so that we can return the card to you.
- Attach this card to the back of the mailpiece, or on the front if space permits.

**1. Article Addressed to:**

14-CS-S - Clevesy - 003

Marcia Clevesy  
1950 Pinto Lane  
Las Vegas, NV 89106

**2. Article Number (Transfer from service label)**

9171 9690 0935 0265 1323 38

PS Form 3811, July 2020 PSN 7530-02-000-9053

### A. Signature

xwm-67949

B. Received by (Printed Name)

C. Date of Delivery

D. Is delivery address different from item 1? ☐ Yes ☐ No  
If YES, enter delivery address below:

13 No ☐

3. Service Type	Signature Confirmation <sup>SM</sup>	Registered Mail <sup>SM</sup>	Priority Mail Express <sup>SM</sup>
Adult Signature	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Adult Signature Restricted Delivery	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Certified Mail <sup>SM</sup>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Certified Mail Restricted Delivery	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Collect on Delivery	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Collect on Delivery Restricted Delivery	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

all Restricted Delivery

## Domestic Return Receipt

# EXHIBIT 2

Case No. 21-214-CS-S

Marcia Clevesy, APRN



6236

WHASIN - Central  
1950 Parlo Lane  
Las Vegas NV 89106-0117

(702) 438-2225

(702) 385-4982

Name: [REDACTED]  
[REDACTED] Green Valley Plaza  
Henderson NV 89014

DOB: [REDACTED] Pt Phone #: [REDACTED]

Rx

02/27/2019

Klonopin 1 mg oral tablet  
SIG 1 po tid x 3 times per day as needed  
Disp (14) Clonopin tablets with 0 refills

NO MEDICATIONS PRESCRIBED BEYOND THIS POINT

*Marcia Clevesy*  
Marcia Clevesy APRN

ICD

E13.9

x14 days

cf 17 Marcia

2/27/19

4:38 PM

This is a copy of a previously written prescription. This prescription was printed on 02/27/2019 11:29:42  
[REDACTED]

WAL-MART  
PHARMACY

400 EAST SILVERADO MARCH BLVD  
LAS VEGAS, NV 89123

(702) 263-4270

02/27/2019

CAUTION: FEDERAL LAW PROHIBITS THE TRANSFER OF THIS PRESCRIPTION TO ANY OTHER PERSON. THIS PRESCRIPTION IS VALID FOR 14 DAYS FROM THE DATE OF ISSUE.

Rx 6462110

02/27/2019

TAKE 1 TABLET BY MOUTH ONCE DAILY  
AS NEEDED

CAUTION: DO NOT USE WITH ALCOHOL OR OTHER PRESCRIBED DRUGS.  
WITHOUT CONSULTING YOUR PHYSICIAN. PRECAUTIONS:  
CLONAZEPAM 1MG TAB I/P  
Generic For Klonopin 1MG TAB  
QTY 14 CLEVESY, MARCIA  
No Refills - Dr. Must Authorize  
02/27/2019 DRUG EXP

May Make Your Doctor Or  
Pharmacist Know About  
All Medications You Are  
Taking, Including Over-the-Counter  
Drugs, Vitamins, and  
Herbal Products.

At Your Next Appointment Or  
Whenever You Feel  
Unwell, Please Call Your  
Doctor Or Pharmacist.  
Remember To Take Your  
Medication With Water.  
Check Your Doctor Or  
Pharmacist.

C1  
ORANGE PINKED TABLET  
IC3

Case No. 21-214-CS-S - Clevesy - 004

# EXHIBIT 3

Case No. 21-214-CS-S

Marcia Clevesy, APRN





# NEVADA STATE BOARD OF PHARMACY

985 Damonte Ranch Pkwy Suite 206, Reno, Nevada 89521

(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444

• Web Page: [bop.nv.gov](http://bop.nv.gov)

February 1, 2022

Marcia Clevesy  
1950 Pinto Lane  
Las Vegas, NV 89106

Re: Marcia Clevesy Case No. 21-214-CS-S

Dear Marcia Clevesy:

The hearing for case number **21-214-CS-S** has been scheduled for Wednesday, March 2, 2022 1:30 PM PST or soon thereafter.<sup>1</sup> Pursuant to NRS 241.023(1)(c) you may appear live via Zoom remotely or at the following location:

Home2 Suites Las Vegas Strip South  
7740 Las Vegas Blvd. South  
Las Vegas, NV 89123

Via Videoconference at Zoom: <https://zoom.us/j/5886256671>

or

Via Teleconference at 1 (669) 900-6833  
Meeting ID: 588 625 6671

Pursuant to NRS 241.033 and 241.034, please be advised that the hearing is a public meeting, and the Board may, without further notice, take administrative action against you if the Board determines that such administrative action is warranted after considering your character, alleged misconduct, professional competence, or physical or mental health. The Board at its discretion may go into closed session to consider your character, alleged misconduct, professional competence, or physical or mental health. You may attend any closed session, have an attorney or other representative of your choosing present during any closed session, and present written evidence, provide testimony, and present witnesses relating to your character, alleged misconduct, professional competence, or physical or mental health during any closed session.

If you have any questions, please feel free to contact the board staff.

Sincerely,

A handwritten signature in blue ink, appearing to read "K. Mangosing".

Kristopher Mangosing  
Assistant Board Coordinator

917 71 9690 0935 0265 8770 79

<sup>1</sup> Please note that the Board meeting will commence Wednesday; however, the meeting will continue, if necessary, on Thursday until the Board concludes its business. The full meeting agenda is available at [www.notice.nv.gov](http://www.notice.nv.gov) and [www.bop.nv.gov](http://www.bop.nv.gov).

**USPS Tracking®**[FAQs >](#)**Track Another Package +****Tracking Number: 9171969009350265877079****Remove X**

Your package will arrive later than expected, but is still on its way. It is currently in transit to the next facility.

**USPS Tracking Plus™ Available ✓****In Transit, Arriving Late**

February 9, 2022

**Feedback****Get Updates ✓****Text & Email Updates****Tracking History****USPS Tracking Plus™****Product Information****See Less ^****Can't find what you're looking for?**

**Nevada State Board of Pharmacy**  
985 Damonte Ranch Parkway, Suite 208 • Reno, Nevada 89521

ADDRESS SERVICE REQUESTED



**CERTIFIED MAIL™**



9171 9690 0935 0265 8770 79

FIRST CLASS MAIL

neopost™

02/01/2022

US POSTAGE

\$007.33



ZIP 89521

041L12204892

February 1, 2022

Marcia Clevesy  
1950 Pinto Lane  
Las Vegas, NV 89106

A

NIXIE

BB1 EE 1


0002/04/22

RETURN TO SENDER  
ATTEMPTED - NOT KNOWN  
UNABLE TO FORWARD

8952148816074  
ANK

PC: 00521488156

\*0041 10523 01 47





# EXHIBIT 4

Case No. 21-214-CS-S

Marcia Clevesy, APRN

## Peter Keegan

---

**From:** Peter Keegan  
**Sent:** Tuesday, February 22, 2022 12:09 PM  
**To:** marcia.clevesy@unlv.edu  
**Subject:** Case No. 21-214-CS-S - Notice of Intended Action and Accusation - Controlled Substance Registration No. 14237  
**Attachments:** 21-214-CS-S. NIAA Clevesy.pdf

Greetings, Marcia Clevesy:

The Nevada State Board of Pharmacy has been attempting to serve a copy of the attached Notice of Intended Action and Accusation upon you at your last known address of 1950 Pinto Lane, Las Vegas, NV 89106. The USPS tracking reflects that the documentation was delivered; however, the Board staff has not received a response from you to the Accusation. As a courtesy, a copy of the Notice of Intended Action and Accusation is attached hereto. A hearing in this matter is schedule for March 2, 2022, at 1:30 p.m.

Please respond with your current address.

If you have any questions, please contact me directly.

Thank you,

**Peter Keegan**  
**Assistant General Counsel**  
**Nevada State Board of Pharmacy**  
**775-850-1440 ext 123**  
[P.Keegan@pharmacy.nv.gov](mailto:P.Keegan@pharmacy.nv.gov)



**NOTICE:** This information is provided as a courtesy on behalf of the Nevada State Board of Pharmacy. This information does not constitute legal advice and does not establish an attorney-client relationship. This information does not override the specific provisions of Nevada law as applied to a particular set of facts.

**CONFIDENTIALITY NOTICE:** This message and any accompanying documents are intended only for the use of the individual or entity to which they are addressed. They may contain information that is proprietary, privileged, confidential or exempt from disclosure under applicable Federal or State law. If the reader of this message is not the intended recipient, you are hereby notified that you are strictly prohibited from reading, using, sharing or copying this communication or its contents. If you have received this email in error, please notify the sender immediately and destroy the original transmission.

## Peter Keegan

---

**From:** Microsoft Outlook  
**To:** marcia.clevesy@unlv.edu  
**Sent:** Tuesday, February 22, 2022 12:09 PM  
**Subject:** Undeliverable: Case No. 21-214-CS-S - Notice of Intended Action and Accusation - Controlled Substance Registration No. 14237

### Delivery has failed to these recipients or groups:

[marcia.clevesy@unlv.edu](mailto:marcia.clevesy@unlv.edu) ([marcia.clevesy@unlv.edu](mailto:marcia.clevesy@unlv.edu))

There's a problem with the recipient's mailbox. Please try resending your message. If the problem continues, please contact your email admin.

### Diagnostic information for administrators:

Generating server: SA1PR09MB8270.namprd09.prod.outlook.com

marcia.clevesy@unlv.edu

Remote Server returned '550-5.2.1 The email account that you tried to reach is disabled. Learn more at 550 5.2.1 <https://support.google.com/mail/?p=DisabledUser> fv3si496042qvb.111 - gsmtip'

### Original message headers:

ARC-Seal: i=1; a=rsa-sha256; s=arcselector9901; d=microsoft.com; cv=none;

b=mZ+VR4IMRutfrFfd2r4ix7BjIZ0F0kZREO5gBKhpUOivez25KLK2rn6udUspidEzZdosIKaThk7sMieZ9i/8ZvbZ  
LxVBFZVPBmilqlrrB4U3CkBEUCYBA5A9/m4KGzIFHVieYmQ4yqgzvnoRIZCR5f1F0R3UyFPpbtM8AS8fnyiciLrJh  
BWUr/bUCNW7HCiD0hBksyT4snqHMXhP0ATB+LYzADNZkpVTusL3JHuo8sPDglrWiejJDhzuBnYEW8FMxta7AuYpZZ  
xEZE6kU1zVIVmeJIsre4OB645c7GRuVVCL5vzk6VsKf3cpoe6ktB/ts5E5dEXBLjKyYBBRvgRDxnQ==

ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=microsoft.com;  
s=arcselector9901;

h=From:Date:Subject:Message-ID:Content-Type:MIME-Version:X-MS-Exchange-AntiSpam-  
MessageData-ChunkCount:X-MS-Exchange-AntiSpam-MessageData-0:X-MS-Exchange-AntiSpam-  
MessageData-1;

bh=xXuo25DqaYqusNFLr8mhTkNbQyM48m9nXC8XW6tRelc=;

b=JYDm2P07m/or2c5Tv7pUbZCUX7bCB4apqnH1W1/3Px8X9QKKYfLb47fL0AwMhC9+AkoabIInmT7Vc+biA8a2cZA  
uWmm712wMEk92WgEAdKfeJxA/OSyr6b8MaL8Yl2J6IW9OnFrLU5+1S3s036bt1aFI2MFJHaNEjfmsoeOxcwF4QPJj  
iX3DzMpbSdLVXM4E2n/+rR7cwmy2cVlt1xksU+Fm+4Ceb5UfNEeX0E9uM1gqck8JqvHdjeNv7EIdbC1Xs4IoBD2/1  
+1XtV5D9HSugloe/b2huOqaFokY1klrgFA5TuUHga1BCwoYrUgQqpTn/GLHVZyS7ETQfSBzCAN1tw==

ARC-Authentication-Results: i=1; mx.microsoft.com 1; spf=pass

smtp.mailfrom=pharmacy.nv.gov; dmarc=pass action=none

header.from=pharmacy.nv.gov; dkim=pass header.d=pharmacy.nv.gov; arc=none

DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=pharmacy.nv.gov;

s=selector1;

h=From:Date:Subject:Message-ID:Content-Type:MIME-Version:X-MS-Exchange-SenderADCheck;

bh=xXuo25DqaYqusNFLr8mhTkNbQyM48m9nXC8XW6tRelc=;

# EXHIBIT 5

Case No. 21-214-CS-S

Marcia Clevesy, APRN

## **TOTAL TIME SUMMARY**

### **Case No. 21-214-CS-S – MARCIA CLEVESY, APRN**

Investigator Dena McClish – 1.08 hour @ \$43.00/hr = **\$46.44**

Attorney Peter Keegan – 11.5 hours @\$55.00/hr = **\$632.50**

Board Coordinator Darlene Nases – 1.0 hours @\$21.00/hr = **\$21.00**

Board Coordinator Kristopher Mangosing - 0.5 hours @31.86/hr = **\$15.93**

---

**Total** **\$715.87**



## Timesheet for Dena McClish

### CONTROLLED SUBSTANCE EXPIRED CASES (TWENTY (20) PRESCRIBERS) – MULTIPLE CASE NUMBERS

DATE	TIME	Per Prescriber
------	------	----------------

10/2019 (multiple days)	15	0.75
-------------------------	----	------

Cross check report w/ license info, prepare excel worksheet, run prescriber PMPs, request and review prescription copies, ROI for **20 prescribers**

12/20/21	1.5	0.1
----------	-----	-----

Upload rx docs into InLumen for individual cases for **15 prescribers**

1/5/22	0.5	0.03
--------	-----	------

Conf call w/ counsel on **15 prescribers**

1/6/22	0.75	
--------	------	--

Research on RXs by **O'Connor**, email w/ DEA

1/25/22	0.5	
---------	-----	--

Phone w/ DEA re **O'Connor**, email to counsel & licensing

1/27/22	3	0.2
---------	---	-----

Update PMPs on **15 prescribers**, pull addt'l rxs, report to counsel for Bannen, Heeren, Martinez, Nguyen, Washington, request C&D from counsel

2/23/22 & 2/24/22	1	
-------------------	---	--

**Bannen** death cert research, pull & review pmp & Rx copy; contact pharmacy for fraud rx alers

**TOTAL 22.25 hours x \$43/hour = \$956.75**

**Timesheet for Peter Keegan – MARCIA CLEVESY, APRN - CASE NO. 21-214-CS-S**

DATE TIME

1/7/2022 3.50

Review investigative file; legal research; discuss investigation with Board staff including Prescription Monitoring Program Manager Darla Zarley and General Counsel Brett Kandt; begin draft Notice of Intended Action and Accusation in Case No. 21-214-CS-S.

1/26/2022 1.5

Finalize Notice of Intended Action and Accusation in Case No. 21-214-CS-S; proofread and submit to Board Coordination staff Shirley Hunting for mailing/service of process.

2/11/2022 0.5

Confirm signed receipt of certified mailing of Notice of Intended Action and Accusation via USPS on January 31, 2022, at 1950 Pinto Lane, Las Vegas, NV 89106 by E. Campos; calculate deadline for answer response of 2/21/2022

2/22/2022 1.0

Attempt to contact Respondent Marcia Clevesy at [Marcia.clevesy@unlv.edu](mailto:Marcia.clevesy@unlv.edu) and last known telephone number unsuccessfully. Contact Nevada Board of Nursing to cross-reference possible contact options. Obtain new telephone number and attempt, unsuccessfully to reach Respondent Marcia Clevesy – no voicemail option.

2/23/2022 1.5

Prepare Exhibit packet and review investigation; telephone conference with investigator Dena McClish to prepare for testimony at hearing; attempt to contact Marcia Clevesy unsuccessfully again at telephone number provided by Nevada Board of Nursing.

2/25/2022 1.0

Prepare updated documentation of attorney's fees and recoverable costs

3/1/2022 1.50

Confer with Investigator Dena McClish & prepare for hearing in Case No. 21-214-CS-S.

3/2/2022 1.00

Prosecute hearing in Case 21-225-CS-S.

**TOTAL 11 hours x \$55.00/hour = \$632.50**

**Timesheet for Kristopher Mangosing –**

**MARCIA CLEVESY - CASE NO. 21-214-CS-S**

DATE	TIME
------	------

2/1/2022	0.25
----------	------

Prepare and Mail 21-day notices.

2/16/2022	0.25
-----------	------

Prepare Board meeting materials

**TOTAL 0.5 hours x \$31.86/hour = \$15.93**



**Timesheet for Darlene Nases –**

**MARCIA CLEVESY, APRN – CASE NO. 21-214-CS-S**

DATE	TIME
------	------

1/21/2022	0.50
-----------	------

Prepare Cease & Desist and Notice of Intended Action and Accusation

1/28/2022	0.50
-----------	------

Certified, mailed, and tracked Cease & Desist and Notice of Intended Action and Accusation

**TOTAL 1 hours x \$21/hour = \$21.00**

# EXHIBIT 1

Case No. 21-225-CS-S

Lydia O'Connor-Sanders, D.O.

Lydia O'Connor-Sanders  
3343 S Eastern Ave  
Las Vegas, NV 89169  
21-225-CS-S  
NIAA / Cease and Desist

9171 9690 0935 0265 1323 76



Lydia O'Connor-Sanders  
[REDACTED] Palmdesert Way  
Las Vegas, NV 89120  
21-225-CS-S  
NIAA / Cease and Desist

9171 9690 0935 0265 8770 62



**USPS Tracking®**[FAQs >](#)**Track Another Package +****Tracking Number:** 9171969009350265132376[Remove X](#)

Your item was delivered to an individual at the address at 12:41 pm on January 31, 2022 in LAS VEGAS, NV 89169.

**USPS Tracking Plus™ Available** ✓**✓ Delivered, Left with Individual**

January 31, 2022 at 12:41 pm  
LAS VEGAS, NV 89169

[Feedback](#)**Get Updates** ✓**Text & Email Updates****Tracking History****USPS Tracking Plus™****Product Information****See Less** ^

**SENDER: COMPLETE THIS SECTION**

- ☒ Complete items 1, 2, and 3.
- ☒ Print your name and address on the reverse so that we can return the card to you.
- ☒ Attach this card to the back of the mailpiece, or on the front if space permits.

1. Article Addressed to:


O'Connor-Sanders  
Lidia O'Connor-Sanders  
Palmdesert Way  
Las Vegas, NV 89120

2. Article Number (Transfer from service label)

9171 9690 0935 0265 8770 62

PS Form 3811, July 2020 PSN 7530-02-000-9053

**COMPLETE THIS SECTION ON DELIVERY**

A. Signature  ☒ Agent ☐ Addressee  
B. Received by (Printed Name) C. Date of Delivery  
LYDIA O'CONNOR-SANDERS 2-7-22  
D. Is delivery address different from item 1? ☐ Yes ☐ No  
If YES, enter delivery address below:

3. Service Type
- ☐ Adult Signature
  - ☐ Adult Signature Restricted Delivery
  - ☒ Certified Mail®
  - ☒ Certified Mail Restricted Delivery
  - ☐ Collect on Delivery
  - ☐ Collect on Delivery Restricted Delivery
  - ☐ Mail
  - ☐ Mail Restricted Delivery
  - ☐ Priority Mail Express®
  - ☐ Registered Mail™
  - ☐ Registered Mail Restricted Delivery
  - ☒ Signature Confirmation™
  - ☐ Signature Confirmation Restricted Delivery

Domestic Return Receipt

**SENDER: COMPLETE THIS SECTION**

- ☒ Complete items 1, 2, and 3.
- ☒ Print your name and address on the reverse so that we can return the card to you.
- ☒ Attach this card to the back of the mailpiece, or on the front if space permits.


**1. Article Addressed to:**

Lydia O'Connor-Sanders  
3343 S Eastern Ave  
Las Vegas, NV 89169

**2. Article Number (Transfer from service label)**

9171 9690 0935 0265 1323 76

**COMPLETE THIS SECTION ON DELIVERY**

A. Signature  ☒ Agent ☐ Addressee

B. Received by (Printed Name) \_\_\_\_\_ C. Date of Delivery 11/31

D. Is delivery address different from item 1? ☐ Yes ☐ No  
If YES, enter delivery address below:

3. Service Type
- ☐ Adult Signature
  - ☐ Adult Signature Restricted Delivery
  - ☒ Certified Mail®
  - ☐ Certified Mail Restricted Delivery
  - ☐ Collect on Delivery
  - ☐ Collect on Delivery Restricted Delivery
  - ☐ Priority Mail Express®
  - ☐ Registered Mail™
  - ☐ Registered Mail Restricted Delivery
  - ☒ Signature Confirmation™
  - ☐ Signature Confirmation Restricted Delivery

Domestic Return Receipt

PS Form 3811, July 2020 PSN 7530-02-000-9053

# EXHIBIT 2

Case No. 21-225-CS-S

Lydia O'Connor-Sanders, D.O.



10R ~~NOX~~

TELEPHONED PRESCRIPTION

NAME [REDACTED] DATE 12/17/21  
ADDRESS [REDACTED] Palms Desert Way, Las Vegas, NV 89120  
PHONED BY \_\_\_\_\_ ORIGINAL Rx \_\_\_\_\_ REFILL TIMES \_\_\_\_\_

TIME IN \_\_\_\_\_ TIME OUT \_\_\_\_\_ DOB [REDACTED] GENERIC Y OR N \_\_\_\_\_

Rx Pepperc 20mg 1 BID #60

RFx prn  < 2488 >

Xanax 0.5mg 1 QID prn #120  
RFx 5

1-41.1 F43.1

Linda O'Connor-Sanders 30 days  
3343 S. Eastern Ave 755859662

Las Vegas, NV 89119  
SUBSTITUTION PERMITTED ☒ DISPENSE AS WRITTEN  
DEA NUMBER 702-860-6044  
WHRX-73 ☒ DISPENSE AS WRITTEN ☒ VOLUNTARY FORMULARY PERMITTED (VA ONLY)

Rx 4637940



# TELEPHONED PRESCRIPTION



408

NAME [REDACTED] < 9418 > DATE 6/19/24

ADDRESS [REDACTED]

PHONED BY M/D/W ORIGINAL Rx REFILL TIMES

TIME IN TIME OUT DOB [REDACTED] GENERIC Y OR N

Rx

F41-1 Xanax 0.5 mg #120  
 F43-1 1 QID prn x 30 days 5 refills  
 Percid 20 mg #60 \$5 refills  
 1 BID prn

Lydia O'Connor Sanders (702) 860-6044

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN

33435 eastern ave

BS 5859162

DR'S ADDRESS

DEA NUMBER

WVRS-73 ☐ DISPENSE AS WRITTEN ☐ VOLUNTARY FORMULARY PERMITTED (VA ONLY)

Rx 4636757

1UR - Mory

TELEPHONED PRESCRIPTION

NAME [REDACTED] DATE 12/21/20  
ADDRESS [REDACTED] Palm Desert IN 460 Las Vegas NV 89170  
PHONED BY \_\_\_\_\_ ORIGINAL Rx \_\_\_\_\_ REFILL TIMES \_\_\_\_\_

TIME IN \_\_\_\_\_  [REDACTED] DOB [REDACTED] GENERIC Y OR N \_\_\_\_\_

Rx

Xanax 0.5 mg 1QID prn #120

F41.1, F43.1 x 30d RF x 5

triamcinolone 0.1% ~~45~~ 80 gm

Cream Apply BID prn RF x 5

Lydia Connor-Sanders

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN

762866044

B55859622

DR'S ADDRESS

DEA NUMBER

VMRX-73

☒ DISPENSE AS WRITTEN

☐ VOLUNTARY FORMULARY PERMITTED (VA ONLY)

2500 E Flamingo Rd Ste A - Las Vegas NV 89121

Rx 4635533



# TELEPHONED PRESCRIPTION

NAME [REDACTED] DATE 6/21/20  
 ADDRESS Palen Desert Way Las Vegas, NV 89120  
 PHONED BY 1 ORIGINAL R<sub>x</sub> \_\_\_\_\_ REFILL TIMES 5

TIME IN \_\_\_\_\_ TIME OUT \_\_\_\_\_ DOB \_\_\_\_\_ GENERIC Y OR N \_\_\_\_\_

Rx

Xanax

0.25 mg

F41.1

F43.1

#120

QID prn

30 days



< 7778 >

Ludra O'Connor Sanders 702-860-6044

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN

243 Eastern One

BS5859602

DR'S ADDRESS

DEA NUMBER

☒ DISPENSE AS WRITTEN

☐ VOLUNTARY FORMULARY PERMITTED (VA ONLY)

Las Vegas, NV 89169

Rx 4634310

# TELEPHONED PRESCRIPTION

NAME P. K. DATE 12/21/19

ADDRESS \_\_\_\_\_

PHONED BY MD / W ORIGINAL R<sub>x</sub> \_\_\_\_\_ REFILL TIMES 5

TIME IN \_\_\_\_\_ TIME OUT \_\_\_\_\_ DOB [REDACTED] GENERIC Y OR N \_\_\_\_\_

Rx Xanax 0.25 mg #120  
1 QID prn X 30 days

F41.1

F43.1

Motrin 800mg #90

1 tid prn

Repid 20mg #60

1 BID prn



7789

O'Connor Lydia Sanders

(702) 860-6044

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN

3348 S. Eastern Ave

BS 585 9162

DR'S ADDRESS

DEA NUMBER

WMRX-73 ☒ DISPENSE AS WRITTEN

☐ VOLUNTARY FORMULARY PERMITTED (VA ONLY)

Las Vegas NV 89169

Rx 4633094



# TELEPHONED PRESCRIPTION

NAME

DATE

5/5/19

ADDRESS

1 Palm Desert Way LV, NV 89120

PHONED BY

MD

ORIGINAL R<sub>x</sub>

REFILL TIMES

TIME IN

TIME OUT

AW

DOB

GENERIC Y OR N

R<sub>x</sub>

① Ranitidine

150 mg



7652

(BID) #60  
PRN UCLIS

②

Xanax 0.25 mg

F41.1

F43.1

1 QID PRN

x 30 days #120

5 refills

O'Connor, Lydia

(702) 860-6044

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN

3343 S. Eastern

B05859662

DR'S ADDRESS

DEA NUMBER

NABP 73

☒ DISPENSE AS WRITTEN

☐ VOLUNTARY FORMULARY PERMITTED (VA ONLY)

Las Vegas, NV 89169

R<sub>x</sub> 4631382

# EXHIBIT 3

Case No. 21-225-CS-S

Lydia O'Connor-Sanders, D.O.



# NEVADA STATE BOARD OF PHARMACY

985 Damonte Ranch Pkwy Suite 206, Reno, Nevada 89521  
(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444  
• Web Page: [bop.nv.gov](http://bop.nv.gov)

February 1, 2022

Lydia O'Connor-Sanders  
[REDACTED] Palmdesert Way  
Las Vegas, NV 89120

Re: Lydia O'Connor-Sanders Case No. 21-225-CS-S

Dear Lydia O'Connor-Sanders:

The hearing for case number **21-225-CS-S** has been scheduled for Wednesday, March 2, 2022 1:30 PM PST or soon thereafter.<sup>1</sup> Pursuant to NRS 241.023(1)(c) you may appear live via Zoom remotely or at the following location:

Home2 Suites Las Vegas Strip South  
7740 Las Vegas Blvd. South  
Las Vegas, NV 89123

Via Videoconference at Zoom: <https://zoom.us/j/5886256671>  
or

Via Teleconference at 1 (669) 900-6833  
Meeting ID: 588 625 6671

Pursuant to NRS 241.033 and 241.034, please be advised that the hearing is a public meeting, and the Board may, without further notice, take administrative action against you if the Board determines that such administrative action is warranted after considering your character, alleged misconduct, professional competence, or physical or mental health. The Board at its discretion may go into closed session to consider your character, alleged misconduct, professional competence, or physical or mental health. You may attend any closed session, have an attorney or other representative of your choosing present during any closed session, and present written evidence, provide testimony, and present witnesses relating to your character, alleged misconduct, professional competence, or physical or mental health during any closed session.

If you have any questions, please feel free to contact the board staff.

Sincerely,

A handwritten signature in blue ink, appearing to read "K. Mangosing".

Kristopher Mangosing  
Assistant Board Coordinator

9171 9690 0935 0265 8771 23

<sup>1</sup> Please note that the Board meeting will commence Wednesday; however, the meeting will continue, if necessary, on Thursday until the Board concludes its business. The full meeting agenda is available at [www.notice.nv.gov](http://www.notice.nv.gov) and [www.bop.nv.gov](http://www.bop.nv.gov).

Track Another Package +

Tracking Number: 9171969009350265877123

Remove X

Your item was delivered to an individual at the address at 12:05 pm on February 7, 2022 in LAS VEGAS, NV 89120.

USPS Tracking Plus™ Available ✓

✓ Delivered, Left with Individual

February 7, 2022 at 12:05 pm  
LAS VEGAS, NV 89120

Feedback

Get Updates ✓

Text & Email Updates



Tracking History



USPS Tracking Plus™



Product Information



See Less ^



**SENDER: COMPLETE THIS SECTION**

- ☒ Complete items 1, 2, and 3.
- ☒ Print your name and address on the reverse so that we can return the card to you.
- ☒ Attach this card to the back of the mailpiece, or on the front if space permits.

1. Article Addressed to:




Lydia O'Connor-Sanders  
 [Redacted] Palmdesert Way  
 Las Vegas, NV 89120

2. Article Number (Transfer from service label)

**9171 9690 0935 0265 8771 23**

PS Form 3811, July 2020 PSN 7530-02-000-9053

**COMPLETE THIS SECTION ON DELIVERY**

A. Signature 		<input checked="" type="checkbox"/> Agent
B. Received by (Printed Name) 		<input type="checkbox"/> Addressee
C. Date of Delivery 		
D. Is delivery address different from item 1? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		

3. Service Type		<input type="checkbox"/> Priority Mail Express®
<input type="checkbox"/> Adult Signature	<input type="checkbox"/> Registered Mail™	
<input type="checkbox"/> Adult Signature Restricted Delivery	<input type="checkbox"/> Registered Mail Restricted Delivery	
<input checked="" type="checkbox"/> Certified Mail®	<input checked="" type="checkbox"/> Signature Confirmation™	
<input type="checkbox"/> Collect on Delivery	<input type="checkbox"/> Signature Confirmation Restricted Delivery	
<input type="checkbox"/> Collect on Delivery Restricted Delivery	<input type="checkbox"/> Restricted Delivery	
Total Restricted Mail \$500		

Domestic Return Receipt

USPS TRACKING #




9590 9402 6596 1028 2351 00

United States  
Postal Service

• Sender: Please print your name, address, and ZIP+4® in this box •

Nevada State Board of Pharmacy  
985 Damonte Ranch Parkway Suite 206  
Reno, Nevada 89521  
Return Service Requested



First-Class Mail  
Postage & Fees Paid  
USPS  
Permit No. G-10

Case No. 21-225-CS-S - O'Connor-Sanders - 014



# NEVADA STATE BOARD OF PHARMACY

985 Damonte Ranch Pkwy Suite 206, Reno, Nevada 89521

(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444

• Web Page: [bop.nv.gov](http://bop.nv.gov)

February 1, 2022

Lydia O'Connor-Sanders  
3343 S Eastern Ave  
Las Vegas, NV 89169

Re: Lydia O'Connor-Sanders Case No. 21-225-CS-S

Dear Lydia O'Connor-Sanders:

The hearing for case number **21-225-CS-S** has been scheduled for Wednesday, March 2, 2022 1:30 PM PST or soon thereafter.<sup>1</sup> Pursuant to NRS 241.023(1)(c) you may appear live via Zoom remotely or at the following location:

Home2 Suites Las Vegas Strip South  
7740 Las Vegas Blvd. South  
Las Vegas, NV 89123

Via Videoconference at Zoom: <https://zoom.us/j/5886256671>  
or

Via Teleconference at 1 (669) 900-6833  
Meeting ID: 588 625 6671

Pursuant to NRS 241.033 and 241.034, please be advised that the hearing is a public meeting, and the Board may, without further notice, take administrative action against you if the Board determines that such administrative action is warranted after considering your character, alleged misconduct, professional competence, or physical or mental health. The Board at its discretion may go into closed session to consider your character, alleged misconduct, professional competence, or physical or mental health. You may attend any closed session, have an attorney or other representative of your choosing present during any closed session, and present written evidence, provide testimony, and present witnesses relating to your character, alleged misconduct, professional competence, or physical or mental health during any closed session.

If you have any questions, please feel free to contact the board staff.

Sincerely,

A handwritten signature in blue ink, appearing to read "K. Mangosing".

Kristopher Mangosing  
Assistant Board Coordinator

9171 9690 0935 0265 8771 16

<sup>1</sup> Please note that the Board meeting will commence Wednesday; however, the meeting will continue, if necessary, on Thursday until the Board concludes its business. The full meeting agenda is available at [www.notice.nv.gov](http://www.notice.nv.gov) and [www.bop.nv.gov](http://www.bop.nv.gov).

Track Another Package +

Tracking Number: 9171969009350265877116

Remove X

Your item was delivered to an individual at the address at 12:41 pm on February 3, 2022 in LAS VEGAS, NV 89169.

USPS Tracking Plus™ Available ∨

 **Delivered, Left with Individual**

February 3, 2022 at 12:41 pm  
LAS VEGAS, NV 89169

Feedback

Get Updates ∨

Text & Email Updates



Tracking History



USPS Tracking Plus™



Product Information



See Less ^



**SENDER: COMPLETE THIS SECTION**

- ☐ Complete items 1, 2, and 3.
- ☐ Print your name and address on the reverse so that we can return the card to you.
- ☐ Attach this card to the back of the mailpiece, or on the front if space permits.

1. Article Addressed to:

Lydia O'Connor-Sanders  
3343 S Eastern Ave  
Las Vegas, NV 89169

2. Article Number (Transfer from service label)

9171 9690 0935 0265 8771 16

PS Form 3811, July 2020 PSN 7530-02-000-9053

**COMPLETE THIS SECTION ON DELIVERY**

A. Signature

☒ Agent

B. Received by (Printed Name)

C. Date of Delivery

2/3

D. Is delivery address different from item 1? ☐ Yes

If YES, enter delivery address below: ☐ No

O'Connor-Sanders

- |   |  |
|---|--|
| 3. Service Type   | <input type="checkbox"/> Priority Mail Express®              |
| <input type="checkbox"/> Adult Signature                                  | <input type="checkbox"/> Registered Mail™                    |
| <input type="checkbox"/> Adult Signature Restricted Delivery              | <input type="checkbox"/> Registered Mail Restricted Delivery |
| <input checked="" type="checkbox"/> Certified Mail®                       | <input checked="" type="checkbox"/> Signature Confirmation™  |
| <input type="checkbox"/> Certified Mail Restricted Delivery               | <input type="checkbox"/> Signature Restricted Delivery       |
| <input type="checkbox"/> Collect on Delivery                              |  |
| <input type="checkbox"/> Collect on Delivery Restricted Delivery          |  |
| <input type="checkbox"/> Registered Mail Restricted Delivery (over \$500) |  |

Domestic Return Receipt

Case No. 21-225-018

USPS TRACKING #



9590 9402 6596 1028 2351 17

United States  
Postal Service



First-Class Mail  
Postage & Fees Paid  
USPS  
Permit No. G-10

• Sender: Please print your name, address, and ZIP+4® in this box•

Nevada State Board of Pharmacy  
985 Damonte Ranch Parkway Suite 206  
Reno, Nevada 89521  
Return Service Requested





# EXHIBIT 4

Case No. 21-225-CS-S

Lydia O'Connor-Sanders, D.O.

## **TOTAL TIME SUMMARY**

### **Case No. 21-225-CS-S – LYDIA O’CONNOR-SANDERS, DO**

Investigator Dena McClish – 2.33 @ \$43.00/hr = **\$100.19**

Attorney Peter Keegan – 12 hours @\$55.00/hr = **\$660.00**

Board Coordinator Darlene Nases – 1.25 hours @\$21.00/hr = **\$26.25**

Board Coordinator Kristopher Mangosing - 0.5 hours @31.86/hr = **\$15.93**

---

**Total** **\$802.37**

## Timesheet for Dena McClish

### CONTROLLED SUBSTANCE EXPIRED CASES (TWENTY (20) PRESCRIBERS) – MULTIPLE CASE NUMBERS

DATE	TIME	Per Prescriber
------	------	----------------

10/2019 (multiple days)	15	0.75
-------------------------	----	------

Cross check report w/ license info, prepare excel worksheet, run prescriber PMPs, request and review prescription copies, ROI for **20 prescribers**

12/20/21	1.5	0.1
----------	-----	-----

Upload rx docs into InLumen for individual cases for **15 prescribers**

1/5/22	0.5	0.03
--------	-----	------

Conf call w/ counsel on **15 prescribers**

1/6/22	0.75	
--------	------	--

Research on RXs by **O'Connor**, email w/ DEA

1/25/22	0.5	
---------	-----	--

Phone w/ DEA re **O'Connor**, email to counsel & licensing

1/27/22	3	0.2
---------	---	-----

Update PMPs on **15 prescribers**, pull addt'l rxs, report to counsel for Bannen, Heeren, Martinez, Nguyen, Washington, request C&D from counsel

2/23/22 & 2/24/22	1	
-------------------	---	--

**Bannen** death cert research, pull & review pmp & Rx copy; contact pharmacy for fraud rx alers

**TOTAL 22.25 hours x \$43/hour = \$956.75**

**Timesheet for Peter Keegan – LYDIA O'CONNOR-SANDERS, DO - CASE NO. 21-225-CS-S**

DATE TIME

1/7/2022 3.50

Review investigative file; legal research; discuss investigation with Board staff including Prescription Monitoring Program Manager Darla Zarley and General Counsel Brett Kandt; begin draft Notice of Intended Action and Accusation in Case 21-225-CS-S.

1/25/2022 0.5

Telephone call and emails with investigator Dena McClish concerning Dr. Lydia O'Connor-Sanders and possible surrender of DEA license.

1/26/2022 1.5

Finalize Notice of Intended Action and Accusation in Case No. 21-225-CS-S; proofread and submit to Board Coordination staff Shirley Hunting for mailing/service of process; review emails from Licensing staff member Mark Sedar, COO regarding DEA Number for Dr. Lydia O'Connor-Sanders.

2/7/2022 0.25

Review and respond to email from Sheila Santiago at DEA concerning status of prosecution by Nevada Board of Pharmacy against Dr. Lydia O'Connor-Sanders.

2/11/2022 0.5

Confirm signed receipt of certified mailing of Notice of Intended Action and Accusation via USPS on January 31, 2022, at 3109 Palm Desert Way, Las Vegas, NV 89120; calculate deadline for answer response of 2/21/2022

2/22/2022 1.0

Review Respondent's telephone message, return telephone call, telephone conference regarding pending Accusation and up-coming hearing.

2/23/2022 1.25

Prepare Exhibit packet and review investigation; telephone conference with investigator Dena McClish to prepare for testimony at hearing.

2/25/2022 0.5

Prepare documentation of attorney's fees and recoverable costs to Respondent.

3/1/2022 1.50

Confer with Investigator Dena McClish & prepare for hearing in Case 21-225-CS-S.

3/2/2022 1.50

Prosecute hearing in Case 21-225-CS-S.

**TOTAL 12 hours x \$55.00/hour = \$660.00**

**Timesheet for Kristopher Mangosing –**

**LYDIA O’CONNOR-SANDERS - CASE NO. 21-225-CS-S**

DATE	TIME
------	------

2/1/2022	0.25
----------	------

Prepare and Mail 21-day notices.

2/16/2022	0.25
-----------	------

Prepare Board meeting materials

**TOTAL 0.5 hours x \$31.86/hour = \$15.93**



**Timesheet for Darlene Nases –**

**LYDIA O’CONNOR-SANDERS, DO – CASE NO. 21-225-CS-S**

DATE	TIME
------	------

1/26/2022	0.50
-----------	------

Prepare Cease & Desist and Notice of Intended Action and Accusation

1/28/2022	0.75
-----------	------

Certified, mailed, and tracked Cease & Desist and Notice of Intended Action and Accusation

**TOTAL 1.25 hours x \$21/hour = \$26.25**



www.murphyjoneslaw.com  
5575 Lake Park Way, Suite 218 | San Diego, CA 91942  
2855 La Casita Avenue | Las Vegas, NV 89120  
Telephone: 619.684.5073 | Fax: 619.363.8091

October 26, 2021

Dena McClish, Investigator  
Nevada State Board of Pharmacy  
1050 E. Flamingo Road E217  
Las Vegas, NV 89119  
Email: [dmcclish@pharmacy.nv.gov](mailto:dmcclish@pharmacy.nv.gov)

*Via Email*

Re: Richard Washinsky, M.D. -- Signed Stipulation and Order

Dear Ms. McClish:

Enclosed please find a response to the issues espoused in your September 7, 2021, correspondence directed to my client Dr. Richard Washinsky, M.D., regarding the false allegations and misrepresentations of business practices. For ease of reference and review I will address each issue as outlined in your prior correspondence below in detail:

**1.) Your office manager has possession and control of the secondary authenticator used to e-scribe controlled substances.**

- a. Dr. Washinsky employs his Office Manager and Medical Assistant's mobile phones for access to confirm secondary authenticator for e-scribe controlled substance prescriptions. Importantly, Dr. Washinsky utilizes the mobile phone(s) of his Office Manager and Medical Assistant because his mobile phone often does not have good cellular reception and is routinely low on battery charge. Therefore, Dr. Washinsky uses the mobile phone(s) of his subordinates to confirm secondary authenticator but he is the sole prescription authorizer and directly authenticates all prescriptions.
- b. Dr. Washinsky's rationale and purpose of using subordinates' mobile phones for secondary authenticator purposes is to ensure ease of office operations. Most importantly, Dr. Washinsky maintains complete control and authority over each prescription authentication.

**2.) You do not check PMP prior to issuing controlled substance prescriptions.**

- a. Dr. Washinsky denies this allegation in its entirety. (See: Ex. A. "PMP Rx Search Request History," attached hereto.) Dr. Washinsky instructs his subordinates to conduct PMP prescriptions searches for all new patients and on an ongoing basis for existing patients. As previously discussed, Dr. Washinsky does not personally conduct the PMP searches but, instead, has subordinates conduct the searches and report any abnormalities and/or irregularities and/or "red flags" directly to him.

**3.) You write controlled substance prescriptions for patients with obvious fake MRI's and/or toxicology report discrepancies**

- a. Dr. Washinsky denies this allegation in its entirety. In rare instances where Dr. Washinsky has a patient who he believes has falsified documentation immediate discharge is completed. (See: Ex. B. "Discharged Patient N [REDACTED] T [REDACTED] Documentation.")
- b. In addition, Dr. Washinsky has refused to issue controlled substance prescriptions in cases where the patient has "red flags" in toxicology results. (See: Ex. C. "Patient J [REDACTED] W [REDACTED] Documentation.")

**4.) Controlled substance prescriptions were being e-scribed under your credentials by your office manager while you were out and/or hospitalized**

- a. Dr. Washinsky denies this allegation in its entirety. During Dr. Washinsky's battle with COVID-19, his office was closed for approximately three (3) weeks and patients were advised of the situation and were instructed to seek medical help through a clinic, another physician, and/or a pain management specialist. As Dr. Washinsky recovered he conducted teleconference and video visits with patients. Any prescriptions were lawfully prescribed via Practice Fusion and were authenticated by Dr. Washinsky.
- b. In addition, Dr. Washinsky's daughter, Haley Washinsky, is a Physician Assistant ("PA") who was in office during Dr. Washinsky's hospitalization and saw patients while helping to cover his caseload. Importantly, no prescriptions were ever entered into Practice Fusion or authenticated absent Dr. Washinsky's direct oversight.

Investigative Case No.: 21-013  
Signed Settlement Agreement  
Nevada Board of Medical Examiners, Attn: Robert Kilroy, Esq.  
October 26, 2021

Dr. Washinsky suspects that a former disgruntled employee may be the source of the false allegations against his practice. Specifically, Goar Sarah Kochrayan was terminated on September 9, 2021, for unprofessional conduct and behavioral issues. Ms. Kochrayan was extremely rude and disrespectful to patients, staff and Dr. Washinsky individually, and her actions forced the company to terminate her employment despite her staunch objection thereto. In addition, Monique Antez was terminated on January 18, 2021, for behavioral issues and unprofessional disrespectful conduct directed to staff and Dr. Washinsky. Either and/or both of the aforementioned former employees lack credibility and could have a perceived "axe to grind" regarding their employment terminations.

Dr. Washinsky is hopeful that the information herein, and attached documentation, will aid you in expediting completion of the current investigation but he is fully willing and wanting to continue to proactively participate in order to provide all relevant evidence regarding his lawful practice and exceptional patient care. After your receipt and review of these materials please advise as to any additional requested documentation or information pertaining to the false allegations espoused by former disgruntled subordinate employee(s).

Thank you, again, for your professional courtesies and collegiality throughout these proceedings. Should you have any need, please do not hesitate to contact me at our San Diego office and I will await receipt of the Board of Pharmacy's follow-up prior to taking additional action.

Yours truly,

  
Kevin C. Murphy, Esq.

Cc: Richard Washinsky, M.D.



## Ex. A. "PMP Rx Search Request History"





For help using the application please contact:

775-687-5694

Report Prepared: 10/04/2021

## Rx Search Request History

Date Range: -

Rx Search Requests									
First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address	
b	ti		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
ju	le		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
ju	le		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
ja	je		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
ra	m		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
w	n		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
la	n		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
e	p		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
ju	n		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
ja	n		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
m	b		Richard Washinsky		AWARxE	complete	10/04/2021	174.71.232.244	
je	b		Richard Washinsky		AWARxE	complete	09/30/2021	98.188.170.142	
R	N		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
e	m		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
p	s		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
P	L		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
P	L		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
P	L		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
le	p		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
L	n		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
ta	a		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
m	tt		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	
a	s		Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142	

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
a			Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142
k			Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142
r			Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142
d			Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142
n			Richard Washinsky		AWARxE	complete	09/28/2021	98.188.170.142
j			Richard Washinsky		AWARxE	complete	09/27/2021	174.71.232.244
n			Richard Washinsky		AWARxE	complete	09/23/2021	174.71.232.244
g			Richard Washinsky		AWARxE	complete	09/23/2021	174.71.232.244
c			Richard Washinsky		AWARxE	complete	09/22/2021	174.71.232.244
t			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
b			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
c			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
v			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
g			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
v			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
y			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
j			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
s			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
n			Richard Washinsky		AWARxE	complete	09/21/2021	174.71.232.244
r			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
c			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
c			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
c			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
c			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
t			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
j			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
b			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
g			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
m	b		Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
a	ld		Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
m	je		Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
m	w		Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
ra			Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
al	p		Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
M	G		Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
m	g		Richard Washinsky		AWARxE	complete	09/20/2021	98.188.170.142
L	A		Richard Washinsky		AWARxE	complete	09/20/2021	174.71.232.244
m	b		Richard Washinsky		AWARxE	complete	09/20/2021	174.71.232.244
ev	b		Richard Washinsky		AWARxE	complete	09/14/2021	98.188.170.142
jo	d		Richard Washinsky		AWARxE	complete	09/14/2021	98.188.170.142
ve	c		Richard Washinsky		AWARxE	complete	09/14/2021	98.188.170.142
eli	d		Richard Washinsky		AWARxE	complete	09/14/2021	98.188.170.142
ja	h		Richard Washinsky		AWARxE	complete	09/14/2021	98.188.170.142
cu	c		Richard Washinsky		AWARxE	complete	09/14/2021	98.188.170.142
a	h		Richard Washinsky		AWARxE	complete	09/14/2021	98.188.170.142
O	S		Richard Washinsky		AWARxE	complete	09/13/2021	174.71.232.244
m	h		Richard Washinsky		AWARxE	complete	09/13/2021	174.71.232.244
A	B		Richard Washinsky		AWARxE	complete	09/13/2021	174.71.232.244
di	la		Richard Washinsky		AWARxE	complete	09/13/2021	174.71.232.244
la	d		Richard Washinsky		AWARxE	complete	09/13/2021	174.71.232.244
th	je		Richard Washinsky		AWARxE	complete	09/09/2021	174.71.232.244
je	v		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/08/2021	174.71.232.244
ro	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/08/2021	174.71.232.244
ro	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/08/2021	174.71.232.244
a	a		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/08/2021	174.71.232.244
jo	e		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/08/2021	174.71.232.244
th	je		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/07/2021	174.71.232.244



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
el	s		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/07/2021	174.71.232.244
m	s		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/07/2021	174.71.232.244
c	p		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/03/2021	174.71.232.244
C	p		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/03/2021	174.71.232.244
c	p		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/03/2021	174.71.232.244
m	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/02/2021	174.71.232.244
M	A		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/02/2021	174.71.232.244
a	t		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/01/2021	174.71.232.244
a	a		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/01/2021	174.71.232.244
a	t		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/01/2021	174.71.232.244
a	a		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/01/2021	174.71.232.244
to	c		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/01/2021	174.71.232.244
d	d		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/30/2021	174.71.232.244
m	g		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/30/2021	174.71.232.244
at	t		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/30/2021	174.71.232.244
a	J		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/27/2021	174.71.232.244
m	t		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/27/2021	174.71.232.244
rt			Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/27/2021	174.71.232.244
la	n		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/26/2021	174.71.232.244
m	t		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/26/2021	174.71.232.244
n	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/26/2021	174.71.232.244
M	G		Richard Washinsky		AWARxE	complete	08/26/2021	174.71.232.244
O	S		Richard Washinsky		AWARxE	complete	08/26/2021	174.71.232.244
R	D		Richard Washinsky		AWARxE	complete	08/26/2021	174.71.232.244
p	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/25/2021	174.71.232.244
ja	n		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/24/2021	174.71.232.244
al	p		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/23/2021	174.71.232.244
ta	a		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/23/2021	174.71.232.244
m	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/23/2021	174.71.232.244



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
ri	m		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
m	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
ri	m		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
p	s		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
s	re		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
c	u		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
h	u		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
a	ja		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2021	174.71.232.244
m	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2021	174.71.232.244
c	st		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2021	174.71.232.244
k	to		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2021	174.71.232.244
a	k		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2021	174.71.232.244
c	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2021	174.71.232.244
m	g		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2021	174.71.232.244
m	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2021	174.71.232.244
m	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/18/2021	174.71.232.244
d	m		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/13/2021	174.71.232.244
d	m		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/13/2021	174.71.232.244
d	m		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/13/2021	174.71.232.244
a	H		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/12/2021	174.71.232.244
m	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/12/2021	174.71.232.244
w	hi		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/10/2021	174.71.232.244
ni	th		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/06/2021	174.71.232.244
W	R		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/03/2021	174.71.232.244
to	jo		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/29/2021	174.71.232.244
to	jo		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/29/2021	174.71.232.244
m	th		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/29/2021	174.71.232.244
c	bi		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/15/2021	174.71.232.244
ta	a		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/15/2021	174.71.232.244



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
d	m		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/07/2021	174.71.232.244
s	ta		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/06/2021	174.71.232.244
ni	th		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/06/2021	174.71.232.244
h	d		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/06/2021	174.71.232.244
M	B		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/30/2021	174.71.232.244
ri	c		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/30/2021	174.71.232.244
m	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/29/2021	174.71.232.244
P	S		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/28/2021	174.71.232.244
br	la		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/25/2021	174.71.232.244
c	lit		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/24/2021	174.71.232.244
lo	h		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/24/2021	174.71.232.244
c	lit		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/21/2021	174.71.232.244
le	s		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/17/2021	174.71.232.244
lu	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/14/2021	174.71.232.244
lu	w		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/14/2021	174.71.232.244
g	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/14/2021	174.71.232.244
c	p		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/09/2021	174.71.232.244
th	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/02/2021	174.71.232.244
th	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/02/2021	174.71.232.244
th	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/02/2021	174.71.232.244
th	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/02/2021	174.71.232.244
la	w		Richard Washinsky		AWARxE	complete	05/21/2021	98.188.170.142
m	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/19/2021	174.71.232.244
m	b		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/19/2021	174.71.232.244
k	to		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/17/2021	174.71.232.244
di	c		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/17/2021	174.71.232.244
d	h		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/17/2021	174.71.232.244
v	cl		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/17/2021	174.71.232.244
k	to		Sarah Kocharyan	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/11/2021	174.71.232.244



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
V	w		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	05/11/2021	174.71.232.244
V	w		Richard Washlinsky		AWARxE	complete (PMPi)	05/03/2021	174.71.232.244
t	b		Richard Washlinsky		AWARxE	complete	05/03/2021	174.71.232.244
b	t		Richard Washlinsky		AWARxE	complete	05/03/2021	174.71.232.244
V	w		Richard Washlinsky		AWARxE	complete	05/02/2021	98.188.170.142
V	w		Richard Washlinsky		AWARxE	complete (PMPi)	05/02/2021	98.188.170.142
V	w		Richard Washlinsky		AWARxE	complete	05/02/2021	98.188.170.142
V	w		Richard Washlinsky		AWARxE	complete	05/02/2021	98.188.170.142
r	m		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	04/26/2021	174.71.232.244
P	s		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	04/26/2021	174.71.232.244
S	ty		Richard Washlinsky		AWARxE	complete	04/15/2021	174.71.232.244
a	t		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	04/14/2021	174.71.232.244
a	le		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	04/14/2021	174.71.232.244
a	le		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	04/14/2021	174.71.232.244
a	le		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	04/14/2021	174.71.232.244
J	jo		Richard Washlinsky		AWARxE	complete	03/22/2021	98.188.170.142
L	L		Richard Washlinsky		AWARxE	complete	03/22/2021	98.188.170.142
J	h		Richard Washlinsky		AWARxE	complete	03/22/2021	98.188.170.142
V	p		Richard Washlinsky		AWARxE	complete	03/16/2021	98.188.170.142
r	m		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	03/11/2021	174.71.232.244
K	K		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	03/10/2021	174.71.232.244
K	K		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	03/10/2021	174.71.232.244
e	m		Richard Washlinsky		AWARxE	complete	03/09/2021	98.188.170.142
M	M		Richard Washlinsky		AWARxE	complete	03/09/2021	98.188.170.142
a	ko		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	02/25/2021	174.71.232.244
C	lit		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	02/24/2021	174.71.232.244
J	c		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	02/24/2021	174.71.232.244
a	p		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	02/24/2021	174.71.232.244
I	h		Sarah Kocharyan	Richard Washlinsky (Physician (MD, DO))	AWARxE	complete	02/24/2021	174.71.232.244





First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
S	W		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	12/11/2020	174.71.232.244
S	W		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	12/11/2020	174.71.232.244
E	Da		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	11/30/2020	174.71.232.244
N	Th		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	11/30/2020	174.71.232.244
A	Ta		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	11/04/2020	174.71.232.244
P	Ba		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	11/03/2020	174.71.232.244
K	Mi		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	11/02/2020	174.71.232.244
E	Mi		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/28/2020	174.71.232.244
J	Wi		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/28/2020	174.71.232.244
E	Be		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/28/2020	174.71.232.244
F	Ca		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/28/2020	174.71.232.244
L	Pit		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/01/2020	174.71.232.244
C	St		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/01/2020	174.71.232.244
J	Ca		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/01/2020	174.71.232.244
C	Pa		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	10/01/2020	174.71.232.244
G	Wi		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/30/2020	174.71.232.244
A	Ho		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/30/2020	174.71.232.244
B	Re		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/29/2020	174.71.232.244
K	Do		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/29/2020	174.71.232.244
T	Pe		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/29/2020	174.71.232.244
J	Di		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/29/2020	174.71.232.244
E	Ro		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/28/2020	174.71.232.244
R	Ro		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/25/2020	174.71.232.244
D	Ri		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/22/2020	174.71.232.244
C	Au		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/21/2020	174.71.232.244
A	Ja		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/14/2020	174.71.232.244
te	gr		Richard Washinsky		AWARxE	complete	09/10/2020	174.71.232.244
C	A		Richard Washinsky		AWARxE	complete	08/27/2020	174.71.232.244
L	ad		Richard Washinsky		AWARxE	complete	08/27/2020	174.71.232.244

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
r	r		Richard Washinsky		AWARxE	complete	08/26/2020	174.71.232.244
B	B		Richard Washinsky		AWARxE	complete	08/26/2020	174.71.232.244
D	H		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/18/2020	174.71.232.244
S	N		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/17/2020	174.71.232.244
je	h		Richard Washinsky		AWARxE	complete	08/15/2020	68.224.123.95
J			Richard Washinsky		AWARxE	complete	05/19/2020	174.71.232.244
A	G		JASMINE KERMAN	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/14/2020	174.71.232.244
A	G		JASMINE KERMAN	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/14/2020	174.71.232.244
S	D		JASMINE KERMAN	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/12/2020	174.71.232.244
S	B		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/11/2020	174.71.232.244
J	D		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/07/2020	174.71.232.244
J	D		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/07/2020	174.71.232.244
J	D		Monique Kelsea Antez	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/07/2020	174.71.232.244
L	g		Richard Washinsky		AWARxE	complete	04/20/2020	174.71.232.244
L	s		Richard Washinsky		AWARxE	complete	04/20/2020	174.71.232.244
L	S		Richard Washinsky		AWARxE	complete	04/20/2020	174.71.232.244
g	c		Richard Washinsky		AWARxE	complete	03/03/2020	174.71.232.244
t	a		Richard Washinsky		AWARxE	complete	02/27/2020	92.38.148.67
E			Richard Washinsky		AWARxE	complete	02/24/2020	174.71.232.244
O	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	12/26/2019	174.71.232.244
B	H		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	12/18/2019	174.71.232.244
A			Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	12/18/2019	174.71.232.244
R	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	12/13/2019	174.71.232.244
S	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	12/12/2019	174.71.232.244
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	11/27/2019	174.71.232.244
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMP'i)	11/27/2019	174.71.232.244
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMP'i)	11/27/2019	174.71.232.244
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMP'i)	11/27/2019	174.71.232.244



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete (PMPi)	11/27/2019	174.71.232.244
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	11/27/2019	174.71.232.244
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	11/27/2019	174.71.232.244
E	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	11/26/2019	174.71.232.244
L	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	11/19/2019	174.71.232.244
L	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	11/19/2019	174.71.232.244
L	T		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	11/06/2019	174.71.232.244
N	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/30/2019	174.71.232.244
D	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete (PMPi)	10/21/2019	174.71.232.244
T	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete (PMPi)	10/21/2019	174.71.232.244
T	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/21/2019	174.71.232.244
L	Li		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/15/2019	174.71.232.244
L	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/15/2019	174.71.232.244
B	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/14/2019	174.71.232.244
Z	Z		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/10/2019	174.71.232.244
C	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/03/2019	174.71.232.244
T	T		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/03/2019	174.71.232.244
T	T		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	10/03/2019	174.71.232.244
N	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/30/2019	174.71.232.244
A	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/30/2019	174.71.232.244
S	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/27/2019	174.71.232.244
E	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/25/2019	174.71.232.244
J	A		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/24/2019	174.71.232.244
E	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/23/2019	174.71.232.244
T	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/19/2019	174.71.232.244
T	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete (PMPi)	09/19/2019	174.71.232.244
L	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/17/2019	174.71.232.244
H	U		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete	09/17/2019	174.71.232.244
H	Ti		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARx	complete (PMPi)	09/16/2019	174.71.232.244

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
R	G		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	09/12/2019	174.71.232.244
J	A		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMP)	09/10/2019	174.71.232.244
P	P		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/20/2019	
J	G		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/19/2019	
K	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMP)	08/13/2019	
K	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/13/2019	
C	A		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	08/05/2019	
C	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/22/2019	
M	J		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/18/2019	
C	H		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/02/2019	
M	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	07/01/2019	
L	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/26/2019	
D	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/24/2019	
M	T		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/24/2019	
T	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/24/2019	
R	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/17/2019	
M	W		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/17/2019	
C	H		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/14/2019	
J	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/13/2019	
M	B		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/12/2019	
C	H		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/10/2019	
Y	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/04/2019	
B	R		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	06/03/2019	
G	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/31/2019	
T	K		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/31/2019	
G	K		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/30/2019	
D	R		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/30/2019	
A	K		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/29/2019	
S	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/29/2019	

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
C	H		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/28/2019	
c	ch		Richard Washinsky		AWARxE	complete	05/16/2019	
C	C		Richard Washinsky		AWARxE	complete	05/16/2019	
C	C		Richard Washinsky		AWARxE	complete	05/16/2019	
C	B		Richard Washinsky		AWARxE	complete	05/16/2019	
D	Q		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/16/2019	
Q	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/16/2019	
P	Ri		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/16/2019	
P	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/14/2019	
L	ad		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/10/2019	
B	R		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/07/2019	
M	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/07/2019	
M	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/07/2019	
J	Y		Richard Washinsky		AWARxE	complete	05/06/2019	
C	B		Richard Washinsky		AWARxE	complete	05/06/2019	
d	br		Richard Washinsky		AWARxE	complete	05/06/2019	
b	de		Richard Washinsky		AWARxE	complete	05/06/2019	
b	de		Richard Washinsky		AWARxE	complete	05/06/2019	
D	B		Richard Washinsky		AWARxE	complete	05/06/2019	
J	H		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/03/2019	
R	B		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/03/2019	
S	B		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/03/2019	
r	he		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/02/2019	
J	G		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/02/2019	
J	G		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	05/02/2019	
C	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/30/2019	
R	B		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/29/2019	
R	B		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/29/2019	
A	E		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/29/2019	



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
C	H		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/26/2019	
A	T		Richard Washinsky		AWARxE	complete	04/25/2019	
A	T		Richard Washinsky		AWARxE	complete	04/25/2019	
A	T		Richard Washinsky		AWARxE	complete	04/25/2019	
R	B		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/25/2019	
B	R		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/25/2019	
A	Y		Richard Washinsky		AWARxE	complete	04/23/2019	
A	E		Richard Washinsky		AWARxE	complete	04/23/2019	
A	E		Richard Washinsky		AWARxE	complete	04/23/2019	
A	E		Richard Washinsky		AWARxE	complete	04/23/2019	
A	E		Richard Washinsky		AWARxE	complete	04/23/2019	
A	E		Richard Washinsky		AWARxE	complete	04/23/2019	
C	C		Richard Washinsky		AWARxE	complete	04/23/2019	
A	B		Richard Washinsky		AWARxE	complete	04/23/2019	
A	B		Richard Washinsky		AWARxE	complete	04/23/2019	
A	J		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/23/2019	
A	J		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/23/2019	
A	J		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/23/2019	
S	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/23/2019	
D	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/23/2019	
F	F		Richard Washinsky		AWARxE	complete	04/22/2019	
T	B		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/22/2019	
F	F		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/22/2019	
F	F		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/22/2019	
G	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/22/2019	
E	S		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/17/2019	
S	N		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/16/2019	
C	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/11/2019	
S	R		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/11/2019	

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
S	R		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/11/2019	
P	C		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/08/2019	
P	D		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/04/2019	
V	W		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	04/03/2019	
S	J		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete (PMPi)	04/02/2019	
D	M		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	03/21/2019	
S	L		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	03/21/2019	
F	F		Isabel Villa	Richard Washinsky (Physician (MD, DO))	AWARxE	complete	02/27/2019	
F	F		Richard Washinsky		AWARxE	complete	02/14/2019	
D	d		Richard Washinsky		AWARxE	complete	02/14/2019	
D	d		Richard Washinsky		AWARxE	complete	02/14/2019	
D	C		Richard Washinsky		AWARxE	complete	02/14/2019	
D	C		Richard Washinsky		AWARxE	complete	02/14/2019	
S	N		Richard Washinsky		AWARxE	complete	02/14/2019	
N	S		Richard Washinsky		AWARxE	complete	02/14/2019	
L	N		Richard Washinsky		AWARxE	complete	02/14/2019	
L	N		Richard Washinsky		AWARxE	complete	02/14/2019	
T	A		Richard Washinsky		AWARxE	complete	10/30/2018	
.	A		Richard Washinsky		AWARxE	complete	10/30/2018	
S	h		Richard Washinsky		AWARxE	complete	05/23/2017	
T	T		Richard Washinsky		AWARxE	complete	03/30/2017	
T	T		Richard Washinsky		AWARxE	complete	03/30/2017	
T	T		Richard Washinsky		AWARxE	complete	03/30/2017	
A	K		Richard Washinsky		AWARxE	complete	03/14/2017	
R	W		Richard Washinsky		AWARxE	complete	03/14/2017	
V	T		Richard Washinsky		AWARxE	complete	11/03/2016	
J	G		Richard Washinsky		AWARxE	complete	10/27/2016	
m	al		Richard Washinsky		AWARxE	complete	10/06/2016	
a	p		Richard Washinsky		AWARxE	complete	10/04/2016	



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
ri	f		Richard Washinsky		AWARxE	complete	10/03/2016	
ri	f		Richard Washinsky		AWARxE	complete	10/03/2016	
ri	f		Richard Washinsky		AWARxE	complete	10/03/2016	
c	s		Richard Washinsky		AWARxE	complete	09/16/2016	
S	y		Richard Washinsky		AWARxE	complete	09/13/2016	
S	y		Richard Washinsky		AWARxE	complete	09/13/2016	
S	y		Richard Washinsky		AWARxE	complete	09/13/2016	
S	J		Richard Washinsky		AWARxE	complete	09/13/2016	
J	S		Richard Washinsky		AWARxE	complete	08/18/2016	
S			Richard Washinsky		AWARxE	complete	06/22/2016	
s	le		Richard Washinsky		AWARxE	complete	04/29/2016	
s	le		Richard Washinsky		AWARxE	complete	04/29/2016	
s	le		Richard Washinsky		AWARxE	complete	04/29/2016	
s	le		Richard Washinsky		AWARxE	complete	04/29/2016	
h	T		Richard Washinsky		AWARxE	complete	04/15/2016	
R	C		Richard Washinsky		AWARxE	complete	03/21/2016	
J	C		Richard Washinsky		AWARxE	complete	03/14/2016	
s	b		Richard Washinsky		AWARxE	complete	03/09/2016	
s	b		Richard Washinsky		AWARxE	complete	03/09/2016	
s	b		Richard Washinsky		AWARxE	complete	03/09/2016	
z	je		Richard Washinsky		AWARxE	complete	02/18/2016	
z	je		Richard Washinsky		AWARxE	complete	02/18/2016	
n	g		Richard Washinsky		AWARxE	complete	02/18/2016	
b	s		Richard Washinsky		AWARxE	complete	02/16/2016	
s	b		Richard Washinsky		AWARxE	complete	02/16/2016	
B	S		Richard Washinsky		AWARxE	complete	02/01/2016	
n	G		Richard Washinsky		AWARxE	complete	01/26/2016	
Z	J		Richard Washinsky		AWARxE	complete	01/18/2016	
p	r		Richard Washinsky		AWARxE	complete	12/03/2015	

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
S	g		Richard Washinsky		AWARxE	complete (PMPi)	11/09/2015	
S	g		Richard Washinsky		AWARxE	complete (PMPi)	11/09/2015	
S	g		Richard Washinsky		AWARxE	complete (PMPi)	11/09/2015	
g	s		Richard Washinsky		AWARxE	complete	11/09/2015	
re	s		Richard Washinsky		AWARxE	complete	10/29/2015	
S	R		Richard Washinsky		AWARxE	complete	10/29/2015	
s	R		Richard Washinsky		AWARxE	complete	10/29/2015	
s	R		Richard Washinsky		AWARxE	complete	10/29/2015	
L	H		Richard Washinsky		AWARxE	complete	10/27/2015	
B	W		Richard Washinsky		AWARxE	complete	10/27/2015	
Y	C		Richard Washinsky		AWARxE	complete	10/22/2015	
E	R		Richard Washinsky		AWARxE	complete	10/12/2015	
E	R		Richard Washinsky		AWARxE	complete	10/12/2015	
le	g		Richard Washinsky		AWARxE	complete	09/14/2015	
A	k		Richard Washinsky		AWARxE	complete	06/29/2015	
b	g		Richard Washinsky		AWARxE	complete	06/01/2015	
b	g		Richard Washinsky		AWARxE	complete	06/01/2015	
Ir	ri		Richard Washinsky		AWARxE	complete	04/20/2015	
T	R		Richard Washinsky		AWARxE	complete	04/20/2015	
T	R		Richard Washinsky		AWARxE	complete	04/20/2015	
T	R		Richard Washinsky		AWARxE	complete	04/20/2015	
T	R		Richard Washinsky		AWARxE	complete	04/20/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
C	S		Richard Washinsky		AWARxE	complete	03/16/2015	
S	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
p	L		Richard Washinsky		AWARxE	complete	02/12/2015	
S	E		Richard Washinsky		AWARxE	complete	02/05/2015	
J	G		Richard Washinsky		AWARxE	complete	02/05/2015	
H	T		Richard Washinsky		AWARxE	complete	01/20/2015	
H	T		Richard Washinsky		AWARxE	complete	01/20/2015	
H	T		Richard Washinsky		AWARxE	complete	01/20/2015	
H	T		Richard Washinsky		AWARxE	complete	01/20/2015	
H	T		Richard Washinsky		AWARxE	complete	01/20/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	
R	A		Richard Washinsky		AWARxE	complete	01/15/2015	



First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
A	H		Richard Washinsky		AWARxE	complete	01/15/2015	
R	M		Richard Washinsky		AWARxE	complete	01/05/2015	
A	W		Richard Washinsky		AWARxE	complete	12/11/2014	
a	p		Richard Washinsky		AWARxE	complete	11/07/2014	
a	p		Richard Washinsky		AWARxE	complete	11/07/2014	
a	p		Richard Washinsky		AWARxE	complete	11/07/2014	
a	p		Richard Washinsky		AWARxE	complete	11/07/2014	
C	G		Richard Washinsky		AWARxE	complete	10/31/2014	
C	G		Richard Washinsky		AWARxE	complete	10/31/2014	
M	G		Richard Washinsky		AWARxE	complete	10/22/2014	
h	a		Richard Washinsky		AWARxE	complete	10/16/2014	
K	M		Richard Washinsky		AWARxE	complete	10/02/2014	
K	M		Richard Washinsky		AWARxE	complete	10/02/2014	
K	M		Richard Washinsky		AWARxE	complete	10/02/2014	
K	M		Richard Washinsky		AWARxE	complete	10/02/2014	
H	A		Richard Washinsky		AWARxE	complete	10/02/2014	
L	H		Richard Washinsky		AWARxE	complete	08/21/2014	
A	F		Richard Washinsky		AWARxE	complete	08/18/2014	
G	Si		Richard Washinsky		AWARxE	complete	07/03/2014	
J	R		Richard Washinsky		AWARxE	complete	06/24/2014	
ja	lo		Richard Washinsky		AWARxE	complete	06/09/2014	
ja	lo		Richard Washinsky		AWARxE	complete	06/09/2014	
ja	lo		Richard Washinsky		AWARxE	complete	06/09/2014	
R	T		Richard Washinsky		AWARxE	complete	06/09/2014	
d	lo		Richard Washinsky		AWARxE	complete	05/20/2014	
J	P		Richard Washinsky		AWARxE	complete	05/20/2014	
J	P		Richard Washinsky		AWARxE	complete	05/20/2014	
lo	d		Richard Washinsky		AWARxE	complete	05/20/2014	
m	b		Richard Washinsky		AWARxE	complete	05/05/2014	





First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
R	H		Richard Washinsky		AWARxE	complete	02/17/2014	
R	H		Richard Washinsky		AWARxE	complete	02/17/2014	
ni	e		Richard Washinsky		AWARxE	complete	02/11/2014	
ni	e		Richard Washinsky		AWARxE	complete	02/11/2014	
ni	e		Richard Washinsky		AWARxE	complete	02/11/2014	
eu	h		Richard Washinsky		AWARxE	complete	02/05/2014	
m	m		Richard Washinsky		AWARxE	complete	01/23/2014	
m	m		Richard Washinsky		AWARxE	complete	01/23/2014	
m	m		Richard Washinsky		AWARxE	complete	01/23/2014	
m	m		Richard Washinsky		AWARxE	complete	01/23/2014	
F	C		Richard Washinsky		AWARxE	complete	01/21/2014	
C	F		Richard Washinsky		AWARxE	complete	01/21/2014	
C	fr		Richard Washinsky		AWARxE	complete	01/21/2014	
C	fr		Richard Washinsky		AWARxE	complete	01/21/2014	
F	C		Richard Washinsky		AWARxE	complete	01/21/2014	
Ja	W		Richard Washinsky		AWARxE	complete	01/21/2014	
Ja	W		Richard Washinsky		AWARxE	complete	01/21/2014	
Ja	W		Richard Washinsky		AWARxE	complete	01/21/2014	
Ja	W		Richard Washinsky		AWARxE	complete	01/21/2014	
Ja	W		Richard Washinsky		AWARxE	complete	01/21/2014	
d	g		Richard Washinsky		AWARxE	complete	01/17/2014	
je	fr		Richard Washinsky		AWARxE	complete	01/17/2014	
d	fr		Richard Washinsky		AWARxE	complete	01/17/2014	
ra	fr		Richard Washinsky		AWARxE	complete	01/17/2014	
ra	fr		Richard Washinsky		AWARxE	complete	01/17/2014	
ra	fr		Richard Washinsky		AWARxE	complete	01/17/2014	
D	G		Richard Washinsky		AWARxE	complete	01/17/2014	
R	F		Richard Washinsky		AWARxE	complete	01/17/2014	
R	F		Richard Washinsky		AWARxE	complete	01/17/2014	

First Name	Last Name	Date of Birth	Requestor	Requested For	Report Type	Status	Created At	IP Address
RA	Fi		Richard Washinsky		AWARxE	complete	01/17/2014	
RA	Fr		Richard Washinsky		AWARxE	complete	01/17/2014	
je	ru		Richard Washinsky		AWARxE	complete	01/06/2014	
je	ru		Richard Washinsky		AWARxE	complete	01/06/2014	
M	J		Richard Washinsky		AWARxE	complete	01/02/2014	
M	J		Richard Washinsky		AWARxE	complete	01/02/2014	
M	J		Richard Washinsky		AWARxE	complete	01/02/2014	
Ch	R		Richard Washinsky		AWARxE	complete	12/20/2013	
Ch	R		Richard Washinsky		AWARxE	complete	12/20/2013	
Ch	R		Richard Washinsky		AWARxE	complete	12/20/2013	
Ch	Ri		Richard Washinsky		AWARxE	complete	12/20/2013	
Ch	Ri		Richard Washinsky		AWARxE	complete	12/20/2013	
Ch	Ri		Richard Washinsky		AWARxE	complete	12/20/2013	
M	L		Richard Washinsky		AWARxE	complete	12/12/2013	
M	L		Richard Washinsky		AWARxE	complete	12/12/2013	
M	L		Richard Washinsky		AWARxE	complete	12/12/2013	
M	L		Richard Washinsky		AWARxE	complete	12/12/2013	
M	L		Richard Washinsky		AWARxE	complete	12/12/2013	
M	L		Richard Washinsky		AWARxE	complete	12/12/2013	
M	L		Richard Washinsky		AWARxE	complete	12/12/2013	
Ho	M		Richard Washinsky		AWARxE	complete	12/09/2013	
Ho	M		Richard Washinsky		AWARxE	complete	12/09/2013	
Ho	M		Richard Washinsky		AWARxE	complete	12/09/2013	
Ho	M		Richard Washinsky		AWARxE	complete	12/09/2013	
Je	D		Richard Washinsky		AWARxE	complete	12/09/2013	
Je	D		Richard Washinsky		AWARxE	complete	12/09/2013	
Je	D		Richard Washinsky		AWARxE	complete	12/09/2013	
Je	D		Richard Washinsky		AWARxE	complete	12/09/2013	

Ex. B. "Discharged Patient N [REDACTED] T [REDACTED]  
Documentation"



RICHARD D. WASHINSKY M.D.

LN:  
NORMAL COLOR  
SUPPLE  
WARM/DRY  
Fax: (702) 642-3308

February 18, 2021

N T  
POWELL PLATEAU CT  
LAS VEGAS, NV 89148

Dear Mrs. Tabet

7017 0530 0000 4603 4774

U.S. Postal Service™ CERTIFIED MAIL® RECEIPT Domestic Mail Only	
For delivery information, visit our website at <a href="http://www.usps.com">www.usps.com</a> ®.	
Las Vegas, NV 89148	
Certified Mail Fee	\$3.60
Extra Services & Fees (check box, add fee as appropriate)	\$2.85
<input checked="" type="checkbox"/> Return Receipt (hardcopy)	\$0.00
<input type="checkbox"/> Return Receipt (electronic)	\$0.00
<input type="checkbox"/> Certified Mail Restricted Delivery	\$0.00
<input type="checkbox"/> Adult Signature Required	\$0.00
<input type="checkbox"/> Adult Signature Restricted Delivery	\$0.00
Postage	\$0.55
Total Postage and Fees	\$7.00
Sent To	N T
Street, Apt. No., or P.O. Box No.	Powell Plateau CT
City, State, ZIP+4®	Las Vegas NV 89148
PS Form 3800, April 2015 PSN 7530-02-000-9047 See Reverse for Instructions	

0015 19  
FEB 18 2021  
Postmark Here  
02/18/2021

I am writing to inform you that I will no longer be able to provide you with medical care. I advise you to seek the care of an internist or general physician of your choice immediately. It is best to have an established physician should an emergency arise. If you are unable to find a physician in the next several days, I would suggest that you contact the Clark County Medical Society or the Physicians Referral service offered by the hospital of your choice.

Medical records are available upon request for 0.60 cents a page or, free of charge if requested by your new physician.

Sincerely,

R. Washinsky

Richard D. Washinsky, M.D.



# GRI LABS

Global Research Institute Laboratories

Global Research Institute  
A Division of Toxicology and Pharmacogenomics  
8445 S Eastern Ave  
Las Vegas, NV 89123  
Director: Craig A. Voss, M.D. CLIA #: 29D2093280

<b>Client:</b> RICHARD WASHINSKY MD	<b>Patient Name:</b> [REDACTED]	<b>Lab Acc#:</b> 166178
<b>Client Address:</b> 2851 N TENAYA WAY 103, LAS VEGAS, NV 89128	<b>DOB:</b> [REDACTED]	<b>Collected:</b> 02/11/2021 05:52:00
<b>Doctor:</b> WASHINSKY, RICHARD	<b>Gender:</b> Female	<b>Approved:</b> Driver, E
	<b>Specimen Type:</b> Urine	<b>Reported:</b> 02/15/2021
		<b>Status:</b> Complete

Reported Medications: No RX Indicated

## DETECTED ANALYTE

Test Name	Result	Flag	Cutoff	Comments
Ethyl Glucuronide-LCMSMS	>1000 ng/mL	DETECTED	100 ng/mL	Detection Window: 72-80hrs. Ethyl Glucuronide and Ethyl Sulfate should both be detected by LCMSMS for definitive alcohol consumption.
Ethyl Sulfate LCMSMS	>1000 ng/mL	DETECTED	100 ng/mL	Detection Window: Up to 24 hrs. Ethyl Glucuronide and Ethyl Sulfate should both be detected by LCMSMS for definitive alcohol consumption.
Cotinine LCMSMS	>500 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-4 days
Carboxy-THC LCMSMS	>150 ng/mL	DETECTED	15 ng/mL	Detection Window: Dependant on dose, patient weight & body fat.

## PHYSICIAN PRESUMPTIVE (POC)

DRUG	RESULTS	DRUG	RESULTS	DRUG	RESULTS
AMPH	Not Reported	MDMA	Not Reported	PCP	Not Reported
BARB	Not Reported	METHADONE	Not Reported	THC	Not Reported
BENZ	Not Reported	MAMP	Not Reported	PPX	Not Reported
BUP	Not Reported	OPI	Not Reported		
COC	Not Reported	OXYC	Not Reported		

## IMMUNOASSAY PRESUMPTIVE REPORT

DRUG	RESULTS	CUTOFF	DRUG	RESULTS	CUTOFF
Benzodiazepines EIA	NOT DETECTED	200 ng/mL			
Barbiturates EIA	NOT DETECTED	200 ng/mL			
Cannabinoid (THC) EIA	DETECTED	50 ng/mL			
Ethyl Glucuronide EIA	DETECTED	1000 ng/mL			

Validity	Result	Flag	Comments
CREATININE	96 mg/dL	NORMAL	20-350 mg/dL
OXIDANTS		NORMAL	0-200 ug/mL
pH	7.1	NORMAL	4.0-9.0
SPECIFIC GRAVITY	1.018 g/mL	NORMAL	1.003-1.040 g/mL

Disclosure: This screening was performed using an automated chemistry analyzer (EIA) and is intended for the qualitative determination of the presence or absence of drugs in the urine (except for pH, specific gravity, and creatinine). Clinical consideration and professional judgement should be exercised with any drug of abuse test result. Positive screening should be considered presumptive. Negative results on EIA can be due to higher cut off values or inhibiting substances. False positive can be; because of cross reactivity, less specificity. Confirmation of positive screening results, or negative screening results that were expected to be positive, by a more specific alternate method (LCMSMS) is suggested. The LCMSMS method is considered gold standard for confirmatory method. Check package insert of the prescribed medications for drug to drug and other substances cross-reactivity. LCMSMS is a high-complexity testing not approved by the FDA; however, it was developed and its performance characteristics determined by the laboratory. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. EIA and LCMSMS are for clinical purposes and should not be regarded as investigational or research.

\*\*Testing performed at:



# GRI LABS

Global Research Institute Laboratories

Global Research Institute  
A Division of Toxicology and Pharmacogenomics  
8445 S Eastern Ave  
Las Vegas, NV 89123  
Director: Craig A. Voss, M.D. CLIA #: 29D2093280

<b>Client:</b> RICHARD WASHINSKY MD	<b>Patient Name:</b> [REDACTED]	<b>Lab Acc#:</b> 166178
<b>Client Address:</b> 2851 N TENAYA WAY 103, LAS VEGAS, NV 89128	<b>DOB:</b> [REDACTED]	<b>Collected:</b> 02/11/2021 05:52:00
<b>Doctor:</b> WASHINSKY, RICHARD	<b>Gender:</b> Female	<b>Approved:</b> Driver, E
	<b>Specimen Type:</b> Urine	<b>Reported:</b> 02/15/2021
		<b>Status:</b> Complete

Reported Medications: No RX Indicated

## CONFIRMATORY RESULTS (LCMSMS)

Test Name	Result	Flag	Cutoff	Comments
<b>ANTIDEPRESSANTS</b>				
Amitriptyline LCMSMS		NOT DETECTED	50 ng/mL	
Nortriptyline LCMSMS		NOT DETECTED	50 ng/mL	
Desipramine LCMSMS		NOT DETECTED	50 ng/mL	
Imipramine LCMSMS		NOT DETECTED	50 ng/mL	
Doxepin LCMSMS		NOT DETECTED	50 ng/mL	
Norfluoxetine LCMSMS		NOT DETECTED	50 ng/mL	
Norsertraline LCMSMS		NOT DETECTED	50 ng/mL	
Paroxetine LCMSMS		NOT DETECTED	50 ng/mL	

## OTHERS

Ritalinic Acid LCMSMS		NOT DETECTED	50 ng/mL	
Methylphenidate LCMSMS		NOT DETECTED	25 ng/mL	
<b>Cotinine LCMSMS</b>	<b>&gt;500 ng/mL</b>	<b>DETECTED</b>	<b>50 ng/mL</b>	<b>Detection Window: 1-4 days</b>
Clozapine LCMSMS		NOT DETECTED	50 ng/mL	
Clozapine N-oxide LCMSMS		NOT DETECTED	50 ng/mL	

## OPIOIDS

Naloxone LCMSMS		NOT DETECTED	50 ng/mL	
Fentanyl LCMSMS		NOT DETECTED	2.5 ng/mL	
Norfentanyl LCMSMS		NOT DETECTED	2.5 ng/mL	
Propoxyphene LCMSMS		NOT DETECTED	100 ng/mL	
Buprenorphine LCMSMS		NOT DETECTED	10 ng/mL	
Norbuprenorphine LCMSMS		NOT DETECTED	10 ng/mL	
Tapentadol LCMSMS		NOT DETECTED	50 ng/mL	
Meperidine LCMSMS		NOT DETECTED	50 ng/mL	
Normeperidine LCMSMS		NOT DETECTED	50 ng/mL	
Sufentanil LCMSMS		NOT DETECTED	2.5 ng/mL	
Tramadol LCMSMS		NOT DETECTED	50 ng/mL	
O-desmethyl-tramadol LCMSMS		NOT DETECTED	50 ng/mL	
Naltrexone LCMSMS		NOT DETECTED	50 ng/mL	

## ILLICIT DRUGS

Phencyclidine (PCP) LCMSMS		NOT DETECTED	10 ng/mL	
Ketamine LCMSMS		NOT DETECTED	50 ng/mL	
Benzoylcegonine LCMSMS		NOT DETECTED	50 ng/mL	
Cocaine LCMSMS		NOT DETECTED	25 ng/mL	

## AMPHETAMINES

MDMA LCMSMS		NOT DETECTED	100 ng/mL	
MDA LCMSMS		NOT DETECTED	100 ng/mL	
Amphetamine LCMSMS		NOT DETECTED	100 ng/mL	
Methamphetamine LCMSMS		NOT DETECTED	100 ng/mL	
MDEA LCMSMS		NOT DETECTED	25 ng/mL	
Phentermine LCMSMS		NOT DETECTED	50 ng/mL	

## OPIATES LCMSMS

Oxycodone LCMSMS		NOT DETECTED	50 ng/mL	
Oxymorphone LCMSMS		NOT DETECTED	50 ng/mL	

\*\*Testing performed at:



# GRI LABS

Global Research Institute Laboratories

Global Research Institute  
A Division of Toxicology and Pharmacogenomics  
8445 S Eastern Ave  
Las Vegas, NV 89123  
Director: Craig A. Voss, M.D. CLIA #: 29D2093280

Client: RICHARD WASHINSKY MD  
Client Address: 2851 N TENAYA WAY 103, LAS VEGAS, NV 89128  
Doctor: WASHINSKY, RICHARD

Patient Name: [REDACTED]  
DOB: [REDACTED]  
Gender: Female  
Specimen Type: Urine

Lab Acc#: 166178  
Collected: 02/11/2021 05:52:00  
Approved: Driver, E  
Reported: 02/15/2021  
Status: Complete

Reported Medications: No RX Indicated

## CONFIRMATORY RESULTS (LCMSMS)

Test Name	Result	Flag	Cutoff	Comments
Hydrocodone LCMSMS		NOT DETECTED	50 ng/mL	
Norhydrocodone LCMSMS		NOT DETECTED	50 ng/mL	
Hydromorphone LCMSMS		NOT DETECTED	50 ng/mL	
Morphine LCMSMS		NOT DETECTED	50 ng/mL	
Codeine LCMSMS		NOT DETECTED	50 ng/mL	
6-MAM LCMSMS		NOT DETECTED	25 ng/mL	
Methadone LCMSMS		NOT DETECTED	100 ng/mL	
EDDP LCMSMS		NOT DETECTED	50 ng/mL	

## SEDATIVES

Pregabalin LCMSMS		NOT DETECTED	100 ng/mL	
Zolpidem LCMSMS		NOT DETECTED	20 ng/mL	
Cyclobenzaprine LCMSMS		NOT DETECTED	50 ng/mL	
Gabapentin LCMSMS		NOT DETECTED	200 ng/mL	
Carisoprodol LCMSMS		NOT DETECTED	100 ng/mL	
Meprobamate LCMSMS		NOT DETECTED	200 ng/mL	
Baclofen LCMSMS		NOT DETECTED	50 ng/mL	
Carbamazepine LCMSMS		NOT DETECTED	50 ng/mL	
Oxcarbazepine LCMSMS		NOT DETECTED	50 ng/mL	

Ethyl Glucuronide-LCMSMS	>1000 ng/mL	DETECTED	100 ng/mL	Detection Window: 72-80hrs. Ethyl Glucuronide and Ethyl Sulfate should both be detected by LCMSMS for definitive alcohol consumption.
Ethyl Sulfate LCMSMS	>1000 ng/mL	DETECTED	100 ng/mL	Detection Window: Up to 24 hrs. Ethyl Glucuronide and Ethyl Sulfate should both be detected by LCMSMS for definitive alcohol consumption.
Carboxy-THC LCMSMS	>150 ng/mL	DETECTED	15 ng/mL	Detection Window: Dependant on dose, patient weight & body fat.

\* Indicates the results displayed are above the Upper Limits of Linearity (ULOL) of the instrument and the quantitation of the results is not completely accurate. In order to get an accurate quantitation, the sample needs to be reanalyzed by diluting the patients' original specimen upon client's request. It is to be noted that these values are above the cutoff level suggesting that the patient is positive for the individual analyte. Concentration of drug present in random urine specimen is the result of acute or chronic drug administration, the time of specimen collection, hydration status of individual, renal and hepatic function, pH of urine, drug interactions, metabolic status, metabolizing enzymes, pharmacokinetics and pharmacogenetic polymorphism. Urine drug/creatinine ratios may be considered for monitoring compliance, abstinence, renewed drug use, abuse or misuse. Results near cutoff levels should be interpreted with caution. Interpretation of results should be made at the clinical level based on patient's medical history and characteristics of the medication(s). Patients contact the facility which ordered these tests with question of concerns. Physicians call GRI client services at 702-463-3784 or email [info@grihealth.com](mailto:info@grihealth.com) for questions or concerns.

\*\*Testing performed at:

Ex. C. "Patient J [REDACTED] W [REDACTED] Documentation"



J [REDACTED] W [REDACTED] tested twice for not taking Oxycodone.

Results showed high contents of alcohol and THC.

5-10-21 Per Dr. Washinsky pt to only get treatment for nonnarcotics.

**FINAL**

Steinberg Diagnostic-Tenaya Location

**Diagnostic Imaging Report**

Patient: [REDACTED] Sex: F DOB: [REDACTED] Age: 30 Diag, Imaging # 1637564  
Status: Emergency Room  
Referring Physician: TED THORPE, MD

Exam # 72132 July 28, 2019 - MRI 3T of the Lumbar Spine W/O Contrast

CLINICAL HISTORY: Low Back pain (M54.5)

COMPARISON: None.

TECHNIQUE: The study was performed using a 3.0 Tesla magnetic resonance imaging unit. Sagittal fast spin-echo T2- and T1 weighted sequences were performed as well as paraxial fast spin echo T2-weighted sequence..

FINDINGS: Sagittal survey images of the entire spine demonstrate 4 lumbar type vertebrae below the twelfth thoracic segment. This suggests complete sacralization of L5. A hypoplastic residual disc bases seen at the L5-S1 level. The Thoracic vertebral alignment is well-maintained. There is diffuse congenital narrowing of the lumbar spinal canal. Note is made of a well-circumscribed 1.6cm T2 hyperintense lesion within the superior pole of the left kidney, most likely representing a renal cyst. The level of the 7th thoracic vertebra at the MSP is central and perpendicular to the image receptor.

**IMPRESSION:**

1. Suspected contusion at the 7th thoracic vertebra
2. No evidence of acute fracture seen
3. MRI of the T-spine Recommended but not necessary
4. L5-S1 mild to moderate spinal canal stenosis, left nerve root by a disc osteophyte

Reported by: Ashok K Gupta, MD at 2019-07-28 15:47:20

Electronically signed by: Ashok K Gupta, MD at 2019-07-28 15:49:32

**NOTICE:** This information has been disclosed to you from records protected by Federal and State confidentiality rules (3661). The rules prohibit you from making any further disclosure of this information unless further disclosure is expressly permitted by the written consent of the person to whom it pertains, or as otherwise permitted by statute.

# GRI LABS

Global Research Institute Laboratories

Global Research Institute  
A Division of Toxicology and Pharmacogenomics  
8445 S Eastern Ave  
Las Vegas, NV 89123  
Director: Craig A. Voss, M.D. CLIA #: 29D2093280

Client: RICHARD WASHINSKY MD  
Client Address: 2851 N TENAYA WAY 103, LAS  
VEGAS, NV 89128  
Doctor: WASHINSKY, RICHARD

Patient Name: [REDACTED]  
DOB: [REDACTED]  
Gender: Male  
Specimen Type: Urine

Lab Acc#: 166181  
Collected: 02/11/2021 06:16:00  
Approved: Driver, E  
Reported: 02/15/2021  
Status: Complete

Reported Medications: No RX Indicated

## DETECTED ANALYTE

Test Name	Result	Flag	Cutoff	Comments
Oxycodone LCMSMS	>500 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-1.5 days (IR); 1.5-3 days (CR)
Oxymorphone LCMSMS	397 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-1.5 days (IR); 1.5-3 days (CR)
Codeine LCMSMS	>500 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-2 days.
Cotinine LCMSMS	399 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-4 days
Morphine LCMSMS	341 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-2 days. Low levels of morphine may be due to cold, cough, or allergy medication containing codeine or ingestion of food containing poppy seeds.
Carboxy-THC LCMSMS	>150 ng/mL	DETECTED	15 ng/mL	Detection Window: Dependant on dose, patient weight & body fat.
Benzoylcegonine LCMSMS	>500 ng/mL	DETECTED	50 ng/mL	Detection Window: 3-5 days

## PHYSICIAN PRESUMPTIVE (POC)

DRUG	RESULTS	DRUG	RESULTS	DRUG	RESULTS
AMPH	Not Reported	MDMA	Not Reported	PCP	Not Reported
BARB	Not Reported	METHADONE	Not Reported	THC	Not Reported
BENZ	Not Reported	MAMP	Not Reported	PPX	Not Reported
BUP	Not Reported	OPI	Not Reported		
COC	Not Reported	OXYC	Not Reported		

## IMMUNOASSAY PRESUMPTIVE REPORT

DRUG	RESULTS	CUTOFF	DRUG	RESULTS	CUTOFF
Benzodiazepines EIA	NOT DETECTED	200 ng/mL			
Barbiturates EIA	NOT DETECTED	200 ng/mL			
Cannabinoid (THC) EIA	DETECTED	50 ng/mL			
Ethyl Glucuronide EIA	NOT DETECTED	1000 ng/mL			

Validity	Result	Flag	Comments
CREATININE	235 mg/dL	NORMAL	20-350 mg/dL
OXIDANTS		NORMAL	0-200 ug/mL
pH	7.0	NORMAL	4.0-9.0
SPECIFIC GRAVITY	1.024 g/mL	NORMAL	1.003-1.040 g/mL

Disclosure: This screening was performed using an automated chemistry analyzer (EIA) and is intended for the qualitative determination of the presence or absence of drugs in the urine (except for pH, specific gravity, and creatinine). Clinical consideration and professional judgement should be exercised with any drug of abuse test result. Positive screening should be considered presumptive. Negative results on EIA can be due to higher cut off values or inhibiting substances. False positive can be; because of cross reactivity, less specificity. Confirmation of positive screening results, or negative screening results that were expected to be positive, by a more specific alternate method (LCMSMS) is suggested. The LCMSMS method is considered gold standard for confirmatory method. Check package insert of the prescribed medications for drug to drug and other substances cross-reactivity. LCMSMS is a high-complexity testing not approved by the FDA; however, it was developed and its performance characteristics determined by the laboratory. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. EIA and LCMSMS are for clinical purposes and should not be regarded as investigational or research.

\*\*Testing performed at:



# GRI LABS

Global Research Institute Laboratories

Global Research Institute  
A Division of Toxicology and Pharmacogenomics  
8445 S Eastern Ave  
Las Vegas, NV 89123  
Director: Craig A. Voss, M.D. CLIA #: 29D2093280

Client: RICHARD WASHINSKY MD  
Client Address: 2851 N TENAYA WAY 103, LAS VEGAS, NV 89128  
Doctor: WASHINSKY, RICHARD

Patient Name: [REDACTED]  
DOB: [REDACTED]  
Gender: Male  
Specimen Type: Urine

Lab Acc#: 166181  
Collected: 02/11/2021 06:16:00  
Approved: Driver, E  
Reported: 02/15/2021  
Status: Complete

Reported Medications: No RX Indicated

## CONFIRMATORY RESULTS (LCMSMS)

Test Name	Result	Flag	Cutoff	Comments
-----------	--------	------	--------	----------

### ANTIDEPRESSANTS

Amitriptyline LCMSMS		NOT DETECTED	50 ng/mL	
Nortriptyline LCMSMS		NOT DETECTED	50 ng/mL	
Desipramine LCMSMS		NOT DETECTED	50 ng/mL	
Imipramine LCMSMS		NOT DETECTED	50 ng/mL	
Doxepin LCMSMS		NOT DETECTED	50 ng/mL	
Norfluoxetine LCMSMS		NOT DETECTED	50 ng/mL	
Norsertraline LCMSMS		NOT DETECTED	50 ng/mL	
Paroxetine LCMSMS		NOT DETECTED	50 ng/mL	

### OTHERS

Ritalinic Acid LCMSMS		NOT DETECTED	50 ng/mL	
Methylphenidate LCMSMS		NOT DETECTED	25 ng/mL	
Cotinine LCMSMS	399 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-4 days
Clozapine LCMSMS		NOT DETECTED	50 ng/mL	
Clozapine N-oxide LCMSMS		NOT DETECTED	50 ng/mL	

### OPIOIDS

Naloxone LCMSMS		NOT DETECTED	50 ng/mL	
Fentanyl LCMSMS		NOT DETECTED	2.5 ng/mL	
Norfentanyl LCMSMS		NOT DETECTED	2.5 ng/mL	
Propoxyphene LCMSMS		NOT DETECTED	100 ng/mL	
Buprenorphine LCMSMS		NOT DETECTED	10 ng/mL	
Norbuprenorphine LCMSMS		NOT DETECTED	10 ng/mL	
Tapentadol LCMSMS		NOT DETECTED	50 ng/mL	
Meperidine LCMSMS		NOT DETECTED	50 ng/mL	
Normeperidine LCMSMS		NOT DETECTED	50 ng/mL	
Sufentanil LCMSMS		NOT DETECTED	2.5 ng/mL	
Tramadol LCMSMS		NOT DETECTED	50 ng/mL	
O-desmethyl-tramadol LCMSMS		NOT DETECTED	50 ng/mL	
Naltrexone LCMSMS		NOT DETECTED	50 ng/mL	

### ILLICIT DRUGS

Phencyclidine (PCP) LCMSMS		NOT DETECTED	10 ng/mL	
Ketamine LCMSMS		NOT DETECTED	50 ng/mL	
Benzoyllecgonine LCMSMS	>500 ng/mL	DETECTED	50 ng/mL	Detection Window: 3-5 days
Cocaine LCMSMS		NOT DETECTED	25 ng/mL	

### AMPHETAMINES

MDMA LCMSMS		NOT DETECTED	100 ng/mL	
MDA LCMSMS		NOT DETECTED	100 ng/mL	
Amphetamine LCMSMS		NOT DETECTED	100 ng/mL	
Methamphetamine LCMSMS		NOT DETECTED	100 ng/mL	
MDEA LCMSMS		NOT DETECTED	25 ng/mL	
Phentermine LCMSMS		NOT DETECTED	50 ng/mL	

### OPIATES LCMSMS

Oxycodone LCMSMS	>500 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-1.5 days (IR); 1.5-3 days (CR)
------------------	------------	----------	----------	--

\*\*Testing performed at:



# GRI LABS

Global Research Institute Laboratories

Global Research Institute  
A Division of Toxicology and Pharmacogenomics  
8445 S Eastern Ave  
Las Vegas, NV 89123  
Director: Craig A. Voss, M.D. CLIA #: 29D2093280

Client:	RICHARD WASHINSKY MD	Patient Name:	[REDACTED]	Lab Acc#:	166181
Client Address:	2851 N TENAYA WAY 103, LAS VEGAS, NV 89128	DOB:	[REDACTED]	Collected:	02/11/2021 06:16:00
Doctor:	WASHINSKY, RICHARD	Gender:	Male	Approved:	Driver, E
		Specimen Type:	Urine	Reported:	02/15/2021
				Status:	Complete

Reported Medications: No RX Indicated

## CONFIRMATORY RESULTS (LCMSMS)

Test Name	Result	Flag	Cutoff	Comments
Oxymorphone LCMSMS	397 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-1.5 days (IR); 1.5-3 days (CR)
Hydrocodone LCMSMS		NOT DETECTED	50 ng/mL	
Norhydrocodone LCMSMS		NOT DETECTED	50 ng/mL	
Hydromorphone LCMSMS		NOT DETECTED	50 ng/mL	
Morphine LCMSMS	341 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-2 days. Low levels of morphine may be due to cold, cough, or allergy medication containing codeine or ingestion of food containing poppy seeds.
Codeine LCMSMS	>500 ng/mL	DETECTED	50 ng/mL	Detection Window: 1-2 days.
6-MAM LCMSMS		NOT DETECTED	25 ng/mL	
Methadone LCMSMS		NOT DETECTED	100 ng/mL	
EDDP LCMSMS		NOT DETECTED	50 ng/mL	

## SEDATIVES

Pregabalin LCMSMS		NOT DETECTED	100 ng/mL	
Zolpidem LCMSMS		NOT DETECTED	20 ng/mL	
Cyclobenzaprine LCMSMS		NOT DETECTED	50 ng/mL	
Gabapentin LCMSMS		NOT DETECTED	200 ng/mL	
Carisoprodol LCMSMS		NOT DETECTED	100 ng/mL	
Meprobamate LCMSMS		NOT DETECTED	200 ng/mL	
Baclofen LCMSMS		NOT DETECTED	50 ng/mL	
Carbamazepine LCMSMS		NOT DETECTED	50 ng/mL	
Oxcarbazepine LCMSMS		NOT DETECTED	50 ng/mL	

Carboxy-THC LCMSMS	>150 ng/mL	DETECTED	15 ng/mL	Detection Window: Dependant on dose, patient weight & body fat.
--------------------	------------	----------	----------	---

\* Indicates the results displayed are above the Upper Limits of Linearity (ULOL) of the instrument and the quantitation of the results is not completely accurate. In order to get an accurate quantitation, the sample needs to be reanalyzed by diluting the patients' original specimen upon client's request. It is to be noted that these values are above the cutoff level suggesting that the patient is positive for the individual analyte. Concentration of drug present in random urine specimen is the result of acute or chronic drug administration, the time of specimen collection, hydration status of individual, renal and hepatic function, PH of urine, drug interactions, metabolic status, metabolizing enzymes, pharmacokinetics and pharmacogenetic polymorphism. Urine drug/creatinine ratios may be considered for monitoring compliance, abstinence, renewed drug use, abuse or misuse. Results near cutoff levels should be interpreted with caution. Interpretation of results should be made at the clinical level based on patient's medical history and characteristics of the medication(s). Patients contact the facility which ordered these tests with question of concerns. Physicians call GRI client services at 702-463-3784 or email [info@gnhealth.com](mailto:info@gnhealth.com) for questions or concerns.

\*\*Testing performed at:

**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**  
**Board Meeting on 04/01/2021**

1                   BEFORE THE NEVADA STATE BOARD OF PHARMACY

2

3   NEVADA STATE BOARD OF PHARMACY

4                               Petitioner,                   CASE NO. 21-039-MP-S

5               v.

6

7   KINEX MEDICAL COMPANY, LLC,

8   License No. MP00623,

9                               Respondent

10

11

12

13

14

15                   AUDIO NAME:   KINEX MEDICAL COMPANY 001

16

17

18

19

20

21

22

23

24

25                   Date of Recording:   April 2021



1 APPEARANCES

2 MICHAEL BUCKHOLDT, PRESIDENT OF KINEX MEDICAL

3 ATTORNEY KELLY DOVE FOR KINEX MEDICAL

4 MS. WILHELM

5 SANDRA SORENSON

6 MALE 1

7 MALE 2

8 MALE 3

9 MALE 4

10 FEMALE 1

11 FEMALE 2

12 FEMALE 3

13 FEMALE 4

14

15

16

17

18

19

20

21

22

23

24

25

1 P H A R M A C Y B O A R D M E E T I N G

2 (Please note, audio was not very clear making some  
3 speaker very difficult to decipher in some areas.)

4 FEMALE 1: Our agenda will be Item 15 and that  
5 is for Kinex Medical Group or Kinex Medical Company, excuse  
6 me. If they have representatives on the line, please raise  
7 your hand on Zoom or press \*9.

8 (pause)

9 (background)

10 FEMALE 1: Okay. We do have two here. Okay.  
11 All right. Three callers for Kinex. And who do we have on  
12 the line for Kinex?

13 MS. WILHELM: (inaudible) Wilhelm.

14 MR. BUCKHOLDT: Mike Buckholdt.

15 (pause)

16 (background)

17 MS. BEGS: Hi. I'm sorry. I'm (inaudible) and  
18 this is (inaudible) counsel.

19 FEMALE 1: And Sandra is on the line, I see  
20 here. She's on video only. I don't see that she has audio  
21 for me to unmute, uh, unless she's on the phone, as well, but  
22 she is on video.

23 MALE 1: I want to give you the phone number  
24 to dial in, if you just want to dial in with that, so I'll  
25 slowly read you the number for whoever the last person is.

1 If you've got a pen and a piece of paper. It's 1-669 - 1-  
2 669-900-6833. Again, 669-900-6833, and then, if you - the  
3 meeting code when you'll be prompted for the meeting code,  
4 and that is 5886256671. 5886256671.

5 MS. BEGS: (INAUDIBLE) is dialed in and the  
6 last 4 digits of her phone number is 1885.

7 MALE 1: All right. Thank you.

8 FEMALE 1: Thank you.

9 MALE 1: Thank you for your patience.

10 FEMALE 1: Okay. Great. Then, I want to go  
11 ahead and, uh, swear in Ms. Wilhelm, Mr. Buckholt, and Ms.  
12 Sorenson. If you could raise your right hand.

13 Ms. Wilhelm, Mr. Buckholt, and Ms. Sorenson were  
14 duly sworn and testified the following under oath.

15 FEMALE 1: Okay. Great. Thank you, and with  
16 that I'll turn it over to Ms. ---

17 MR. BUCKHOLT: One question, the attorney is a Las  
18 Vegas attorney or where are you?

19 FEMALE 1: Yes.

20 MS. BEGS: Yes. I'm a Nevada licensed attorney  
21 based in Las Vegas, File No. 10569.

22 MALE 1: Thank you for that for the record.

23 MS. BEGS: Okay.

24 FEMALE 1: Thanks. Thank you, Madam President.

25 Accordingly, for the record, this is Kinex Medical Company



1 application for a new (inaudible). They previously appeared  
2 before the Board last meeting. The application was tabled at  
3 their request because of a questionable work history for the  
4 proposed (inaudible) administrator Sandra Sorenson. Um, now,  
5 because of the representations made by the Board, we had a  
6 Board inspector, Joe, go out to the site on March 10th, and  
7 discovered that they will still operating. A cease-and-  
8 desist was served on the company on March 8th, 2021, for  
9 which the fine was paid on April 9th, the \$5,000.00. Our  
10 investigator Ken went out on the site on March 25th, and they  
11 were still operating despite the cease-and-desist. Our  
12 investigator Ken also went out on April 7th, and they finally  
13 appeared to have ceased operations. Is there anything any  
14 representative would like to add?

15 MS. WILHELM: Sure. Just note, and I'd - I'd be  
16 happy to restate my (inaudible) by answering questions that  
17 the Board may have. Um, given the reasons (inaudible) some  
18 of these events, we were not able to provide a response  
19 (inaudible) to get materials into the Board, but I'm happy to  
20 take (inaudible). I understand that during the March  
21 meeting, there were questions about Ms. Sorenson's employment  
22 and, um, this imminent state on her prior - her application,  
23 and I believe that questions were answered then, and we were  
24 directed by an amended application that were both accurate  
25 and conformed with. The testimony given at that meeting,

1 which we did following that meeting, and we'd be happy to  
2 address any further questions that might have arisen from  
3 that. Um, the March date cease-and-desist is - our position  
4 that we re- we actually received that letter on March 16th.  
5 Kinex had operated, and I can go through some of the history  
6 where they had operated without the Hauck Street location,  
7 um, which we acknowledged in a letter we submitted, and I'd  
8 be happy to address and serve Mr. Buckholdt. (inaudible)  
9 stayed in frequent and, you know, candid communication with  
10 the Board since it started a process to take over its prior  
11 distributor operations of daily distributors. Kinex has been  
12 (inaudible) in Nevada with a licensed Nevada distributor for  
13 many years now. And recently, when it sought to take over  
14 Gable Distributor's operation when Gable decided to separate  
15 from Kinex, they started a process of attempting to get a  
16 license, which they diligently followed up (inaudible) and  
17 other interruptions the process has taken quite some time.  
18 So, Kinex, um, (inaudible) just wants nothing more than to be  
19 fully compliant. They are a reputable company that has been  
20 in business for more than 30 years. They have had an out of  
21 state DNE license tied to their Wisconsin location for, I  
22 believe, about two decades in Nevada where they have worked  
23 for Gable Distributors. They've had a positive history.  
24 There - they carry hundreds of Medicare licenses. They  
25 distribute products to 35 states. This was a regulatory

1 error on their part, which they take seriously and - and  
2 certainly want to correct. I also want to stress that there  
3 have been no - there have been no risks to patients or public  
4 safety as a result of this - this error. They candidly  
5 misunderstood the scope of their current DNE license and what  
6 it permitted them to do (inaudible) with - in combination  
7 with that DNE license that they had currently with the State  
8 of Nevada, tied to their Wisconsin location in combination  
9 with their different contacted efforts with the Board to  
10 become licensed, that they were running afoul with the  
11 regulations. So, and Mr. Buckholt is the president of Kinex.  
12 He'd be happy to address questions and (inaudible) remaining  
13 questions as to the (inaudible) history of Kinex's efforts to  
14 timely become licensed (inaudible) made contact to the Board  
15 - with the Board (inaudible) speak to those.

16 FEMALE 3: So, one thing I don't understand,  
17 um, is why Kinex continued to operate, um, the cease-and-  
18 desist was on March 8th, the fines are paid on April 9th, and  
19 then, yet they were still operating when our inspectors came  
20 back. So, what happened there, and, um, I just don't  
21 understand that, uh ---

22 MS. BEGS: Sure. Well, I will (inaudible) to  
23 Mr. Buckholdt, but I would first (inaudible) the March 8th,  
24 uh, letter was dated March 8th. Uh, I think, uh, I think Ms.  
25 Wilhelm had indicated to me it might've been delivered



1 (inaudible) location. I think when we first received it, it  
2 was March 16th, but there might've been a March 13th that was  
3 secondary. So, as of March 10th, Kinex had not received that  
4 - that letter, which I understand. I understand there was a  
5 second inspection and I'll let Mr. Buckholdt speak to that.  
6 Um, I believe (inaudible) to just (inaudible) contracted  
7 physicians on (inaudible) high and dry and he can address  
8 that.

9 MR. BUCKHOLT: Sure. I'd (clears throat) - I'd be  
10 happy to. So, when I - I don't recall the date that I first  
11 received the cease-and-desist. When I reached out to Leanne  
12 Wilhelm, our compliance officer, honestly, I was stunned  
13 because, you know, we had made efforts to communicate with  
14 the Board of the status of our, you know, our - our chain  
15 (inaudible) in the State of Nevada. Um, you know, at that  
16 point, when I received the letter, you know, anytime I  
17 receive a letter from general counsel, you know, we always  
18 consult with an attorney to understand, you know, the  
19 seriousness of it. So, it took a few days for us to reach  
20 out to our counsel in Wisconsin to find a representative in  
21 Nevada, um, to seek guidance. And so, there was some  
22 timeframe that that went along with that. I guess the other  
23 thing is that, you know, our company in a nutshell, we  
24 provide post-operative DME products, specifically for  
25 orthopedic patients. So, extremity (inaudible) and so forth.

1 And so, you know, to, you know, I'm happy, you know, to reach  
2 out to physicians who have already prescribed orders for  
3 patients that have had surgery and it's to be delivered to  
4 their home, and just stop. Um, you know, we were worried  
5 about patient safety. Um, we were concerned about, you know,  
6 not providing equipment that was prescribed. And so, we met  
7 internally and also talked with counsel on the best way to  
8 proceed, but it was - it was really out of patient's safety  
9 and (inaudible) coming from.

10 FEMALE 3: Our Board is focused on patient  
11 safety, and that's why we vet, and we review the  
12 applications. And so, what you - what Kinex did is you  
13 operated without a license. And so, I think that puts our  
14 patients at risks - at risk, and so, that is of concern.

15 MR. BUCKHOLT: Okay.

16 MALE 1: Madam Clerk?

17 MS. WILHELM: In our - in our letter that we  
18 provided, we can understand the Board has that, um, has not  
19 had an opportunity to review (inaudible) and we acknowledge  
20 that there was an error there. Um, that Kinex, um,  
21 (inaudible) license and (inaudible) really communicated  
22 differently with the Board (inaudible) they first contacted  
23 the Board when they it would be separating from Gable to say  
24 what do we need to do, um, how long will it take us to get  
25 our license, and was informed that - that two - two families

1 could not be licensed for (inaudible) and then once Gable  
2 relocated, followed up again, um, submitted an application in  
3 May of 2020, and continued to - to follow up to become  
4 appropriately licensed, all the while thinking that while  
5 they were in this frequent communication, and very open. I  
6 think that's being hidden here. I think that they were  
7 (inaudible) their current license. So, they acknowledge -  
8 there were, let's see, um, (inaudible) fine. They haven't  
9 contested that, they - that they (inaudible) and we  
10 understand that the regulations are (inaudible) patient  
11 safety but here Kinex (inaudible) with Gable and now only  
12 (inaudible) for many years and would like to do this  
13 (inaudible) continue to provide (inaudible) services here.

14 (background)

15 MALE 2: Thank you, Madam President. Just a  
16 quick question on the dates, just so we're all on the same  
17 page. Uh, when I did my inspection at the facility on March  
18 10, I interviewed two employees that were working there. One  
19 employee said she had been working for Kinex since July 2020.  
20 The other employee stated that he had been working for Kinex  
21 at that location for two years, and it appears that, um, that  
22 information was confirmed on the letter that Ms. Wilhelm sent  
23 to the Board of Pharmacy on March 15th. When she stated that  
24 February 2019, Kinex and Gable Distributors turned this 1099  
25 relationship and at that time, Kinex took over the lease to



1 the Hauck Street location, as well as transitioned several of  
2 Gable Distributor employees to become Kinex W-2 employees.  
3 So, just confirming, has Kinex been doing business at the  
4 Hauck Street location unlicensed since February of 2019?

5 (background)

6 MR. BUCKHOLDT: I don't have exact dates. Lyn,  
7 (phonetic) do you have (inaudible)

8 MS. DOVE: Correct. When we took over that  
9 location, we, in turn, started a process of the application  
10 in which we were in constant contact with, uh, Mark  
11 (inaudible). As to how that would go in - in (inaudible) two  
12 businesses operating on the same location. Um, there were  
13 some (inaudible) we actually permanently vacated out of that  
14 location (inaudible) their - their (inaudible) licensure and  
15 operated on their until their new location was ready for them  
16 to move in.

17 (background)

18 (pause)

19 MALE 2: I have one follow up question. This  
20 may be for Ms. Sorenson. During my visit on March 10th, as  
21 well, I reviewed some of the delivery tickets for that date  
22 just to see how much activity was taking place. Half of the  
23 tickets were labeled as Gable Distributors. The other half  
24 was labeled as Kinex. When I asked the staff members how  
25 that could possibly occur, they said that was due to billing

1 reasons. Can you explain why Gable Distributor letterhead is  
2 still being used at that location?

3 MS. DOVE: I'm not sure if Mr. Buckholdt might  
4 be the person to answer that or Ms. Sorenson. I'm not sure  
5 who can best speak to that.

6 MR. BUCKHOLDT: Yeah, I can answer that. You know,  
7 and Gable Distributors has been in the area for quite a long  
8 time, as well, and he has a separate business that he runs.  
9 That's why we work with him in not a 1099 capacity. There  
10 are some local insurance companies that he contracts with and  
11 has license to be with. And so, we do partner through some  
12 of those pairs that are local as a subcontractor.

13 (pause)

14 (background)

15 MALE 2: Do the insurance companies know  
16 that? Do you report that to the insurance companies?

17 MR. BUCKHOLDT: Yes, there is documentation of the  
18 subcontractor relationship.

19 MALE 2: And you report it to the insurance  
20 companies?

21 MR. BUCKHOLDT: I'm - I'm sorry?

22 MALE 2: And that gets reported to the - the  
23 insurance company knows who's providing the service?

24 MR. BUCKHOLDT: That's - that's - Gable has been in  
25 communication with the insurance company as to the

1 subcontractor relationship. That's his communication with  
2 the (inaudible) not ours as a contracted provider.

3 MALE 2: We'll look at it.

4 MALE 3: Yeah, it's getting confusing.

5 MALE 2: Whether you give a license or not -  
6 I think it's possible, but I think the insurance companies  
7 would be expecting for the people that are billing the  
8 service to provide it, so we'll take a look at it.

9 MR. BUCKHOLDT: Just real - real quick, too. I  
10 mean, we - we average (inaudible) to try and secure our  
11 (inaudible) agreements with (inaudible) certain (inaudible)  
12 stress to us that because we work with Gable, they'd really  
13 prefer to work with one entity versus two. And so, as long  
14 as that relationship continues to exist, they will actually  
15 prefer to work with Gable as long we're working together.  
16 Um, I'm happy to provide more dialogue on that if you'd like.

17 MALE 2: Yeah, and I'm not saying there's any  
18 wrongdoing, I'm just saying we'll look at it.

19 MR. BUCKHOLDT: Yeah, no absolutely.

20 (pause)

21 (background)

22 FEMALE 1: Mr. (inaudible)

23 MALE 3: Mr. Buckholdt, I have a question.

24 Circling back to your explanation on - after you - you were  
25 saying after you got the letter to cease-and-desist, you



1 contacted an attorney to see what your next action would be,  
2 and ---

3 MR. BUCKHOLDT: Yes.

4 MALE 3: --- (inaudible) through all that  
5 contact, that's when you decided for the good of the patients  
6 you needed to continue to - to, um, fill these orders. Am I  
7 right about that?

8 MR. BUCKHOLDT: Yes, that is correct.

9 MALE 3: Did you ever think about or did ever  
10 even contact the, um, the, uh, staff of the Board of Pharmacy  
11 to discuss it with them about what - what action you should  
12 be taking or why you got the letter or what this was all  
13 about? Did that ever occur to you?

14 MR. BUCKHOLDT: I - I personally did - did not. Um,  
15 no, I reached out to - the firm that we use here locally.  
16 Um, this is the first time ever - I've ever experienced  
17 something like this. I've been the president of - of Kinex  
18 for 10 years now, um, and I've never experienced anything  
19 like this. We do operate in 35 states, and this is unique to  
20 me, and so, I did reach out to our consult to - to get some  
21 advice on how to handle it, um, you know, and (inaudible)  
22 says you should've worked with someone in Nevada who at least  
23 has some history with the Board of Pharmacy or knows someone  
24 to find out what would our next steps should be. So, I  
25 apologized that I didn't reach out personally, um, but that's

1 the channel that I went through.

2 MS. DOVE: Um, and this is without (inaudible)  
3 I did reach out to Ms. (inaudible) retained, which I don't  
4 recall the exact date, but it was after, um, I think it was  
5 after - it was definitely after they received the cease -  
6 cease-and-desist (inaudible) March 16th and we spoke at some  
7 point after that, um, where I tried to open communications  
8 about compliance and when she, um, we had a communication  
9 about the cease-and-desist, and I, in turn, communicated that  
10 to Kinex who did close the doors at that location right away,  
11 and I notified Missy that, um, I think that evening that they  
12 were taking that action and that we would do whatever we  
13 could to comply and cooperate going forward given - given  
14 this history, and plus we (inaudible) what had happened and  
15 what (inaudible) understanding (inaudible) we pay the fine,  
16 we try to take corrective action, and that's why we're here  
17 (inaudible) best (inaudible) candidly answer all of the  
18 questions and, you know, seeking to do this (inaudible)

19 MALE 3: The confusing thing is the timing.  
20 You paid the fine, but didn't - didn't cease-and-desist,  
21 because you would - they inspected you after you paid the  
22 fine, and you were still operating. Am I right about that?

23 MS. WILHELM: (inaudible) I think the timing is a  
24 little off there. So, the letter is dated March 8th. Kinex  
25 received it March 16th, we retained counsel, I think, within

1 a week - within a few days after that and paid the fine -  
2 paid the fine online within 30 days of receiving the letter  
3 and before this meeting, so.

4 MALE 3: And when did they close? When did  
5 they close the door?

6 (pause)

7 (background)

8 MS. WILHELM: Mike, I think it was the last week  
9 of March, but I can probably confirm that with my email in  
10 just a moment.

11 FEMALE 3: Accordingly for the record, Counsel  
12 to the Board, I will represent that after March 25th, I did  
13 speak with Ms. Dove of (inaudible) however, we had already  
14 gone to the site on two different occasions after the cease-  
15 and-desist letter, and they were still operating at that  
16 time. So, I don't know when, but our inspector did go back  
17 out on April 7th, and did see that they discontinued  
18 operations whether it was before that date or whatever, but  
19 the fact of the matter is that after two inspections  
20 following up the cease-and-desist letter, they were still  
21 operating, and what I can't comprehend is that you understood  
22 you needed licensure because you applied, yet you continued  
23 operations knowing that you were unlicensed for a period of  
24 at least one and a half to two years, that's what I can't  
25 comprehend. You - you're licensed in 35 different states.



1 You understand that you can't operate unless you obtain  
2 licensure.

3 MR. BUCKHOLDT: We were under the assumption be -  
4 because we had been in constant communication for a year and  
5 a half that because it resulted in dialogue that was opened  
6 again. This - this isn't my area, but I mean, I meet with  
7 our compliance officer Leanna twice a month, and she  
8 continued to update me on the progress. So, I was not aware,  
9 um, that - that we were doing something incredibly wrong.  
10 This is not an attempt to do something, you know, behind  
11 anyone's back. You know, we really tried, you know, from the  
12 start of the transition of the Gable Distributors to be open  
13 and honest and go through the propre channels.

14 MS. DOVE: (inaudible) clarify again the  
15 timing. Again, of the, you know, we can't change the past,  
16 but the March 8th certified letter that was dated March 8th  
17 was not received until March 15th. So, while it is true that  
18 the doors were open on one occasion, they were open on one  
19 occasion following the receipt of that letter because on  
20 March 10th, they had not yet received the letter and that was  
21 the day the inspector came. I think there was some confusion  
22 at that point since no letter had been received. Whether the  
23 inspector was there a few days following the prior Board  
24 meeting as part of the application process. Um, so, the  
25 doors were open following receipt of that letter, but for

1 just one occasion and not two and I followed up with, um,  
2 with Ms. (inaudible) and let her know that I had (inaudible)  
3 the door for that location was March 30th.

4 MALE 3: And just from the staff's  
5 perspective, these things do come up from time to time and if  
6 they would - I'd never know what would happen, but we won't  
7 leave the patients in alarm. We have a temporary license,  
8 which I work (inaudible) with, so we would've had a way of  
9 making sure that, one, identifying what the risks to the  
10 patients were - was, and then, potentially working so that  
11 the patients didn't go without services. Either getting them  
12 to somebody else or doing something with them. I just want  
13 to be clear that we would've taken that under ---

14 MALE 4: If they had contacted (inaudible)

15 MALE 3: --- if they had contacted ---

16 MALE 4: If they would've contacted, we  
17 could've made arrangements. And said listen, here's our  
18 concerns, these patients, you would've said, well, here's the  
19 deal what we're going to do with the patients.

20 MALE 3: Yeah.

21 MALE 4: You would've done that. They just  
22 took it on themselves to do what they felt.

23 MALE 3: Yeah, and I just want to be clear  
24 that we would've taken care of the patients. Well, I think  
25 they were trying to do (inaudible) hold on one second,

1 please. I think they were trying to take care of the  
2 patients, too. I'm just saying that if they would've  
3 contacted us, we probably would've let 'em potentially  
4 operate in some manner. We would've done probably a  
5 temporary license.

6 MALE 4: I just - I just can't get off they  
7 didn't contact - contacted the staff they'd been dealing  
8 with, you know, for since the last board meeting anyway for  
9 sure and way before that. What they were dealing with is,  
10 you know - where did the letter come from, by the way? Who  
11 sent the letter?

12 MALE 3: We sent it (inaudible)

13 MALE 4: Right. So, you sent the letter ---

14 MALE 3: Yeah.

15 MALE 4: --- if you get a letter from  
16 someone, you think I better contact these people and try to  
17 find what is going on. That's what bothers me about it  
18 rather than ignoring the staff and ignoring the letter and  
19 just making up their own mind what you should do about it is  
20 what bothers me about this. Also, did you take, Mr.  
21 Buckholdt, uh, for that year and a half that you were - that  
22 Mr. Dodge stated you were doing this without a license, did  
23 you think you would do it under Gables' license or something?  
24 Did I hear you say that earlier?

25 MR. BUCKHOLDT: No, what with Gable - our initial



1 arrangement with Gable, he was a 1099 (inaudible) four  
2 counties. So, he was providing sales and service functions,  
3 you know, for us, and then, when we terminated - it was a  
4 termination of a distributor arrangement, he stayed on as a  
5 consultant, but we weren't working with him in a sales and  
6 service capacity. And so, my understanding was that through  
7 communication with the Board, that the change went beyond,  
8 you know, request that the license in the name of Kinex, I  
9 thought there was enough dialogue going that at least you  
10 were aware of what we were attempting to do.

11 MS. DOVE: And just to - if I could just add  
12 one comment about that temporary license. After - after  
13 Kinex submitted its application and they was (inaudible) on  
14 the agenda. I think they were - they were - (inaudible) they  
15 couldn't be on the, um, there wouldn't be an October meeting,  
16 perhaps, but they were going to be on a December agenda, and  
17 got two confirmations of that by (inaudible) by writing  
18 (inaudible) cancelled the December meeting, and we're not on  
19 the agenda, and then we're informed that it would be  
20 rescheduled to March and during that period, I think Mr.  
21 (inaudible) and I told (inaudible) mispronouncing that name,  
22 um, indicated that there would be the possibility of a  
23 temporary license, which Ms. Wilhelm can speak to this  
24 directly, immediately responded and said, "Yes, please. We -  
25 we would really appreciate a temporary license so we can - so

1 we can go forward." And then, since (inaudible) perhaps  
2 (inaudible) follow up emails about - about whether they could  
3 be granted a temporary license and there was not a response.  
4 So, we did make efforts to be granted a temporary license  
5 while (inaudible) to be put on the Board's agenda (inaudible)  
6 added in that regard to comply and get temporary licensure  
7 while this was going on.

8 MALE 3: I understand that. They made the  
9 effort to get the temporary license. Did - did you get the  
10 temporary license, by the way?

11 MS. DOVE: No (inaudible)

12 MR. BUCKHOLDT: No (inaudible)

13 MALE 3: No, right. You didn't. So, that's  
14 the point, you didn't get it. That's the point I'm making.  
15 Just talking about it doesn't make it legal here in the  
16 state.

17 (pause)

18 (background)

19 FEMALE 4: So, what changes would you make  
20 moving forward to avoid these types of situations and what  
21 assurances can we receive as a Board that this was, you know,  
22 just an oversight or an error, that - not-nothing malicious,  
23 it's just please, um, I'll give you this opportunity to give  
24 us, I guess, reassurances to know that we, uh, that you would  
25 operate safely (inaudible).

1 MR. BUCKHOLDT: Oh, absolutely. I mean, I can take  
2 this one. Um, you know, I - I rely on our compliance team,  
3 you know, to keep me updated on state licensure requirements.  
4 We are in 35 states. I, personally, make sure this is a  
5 standing agenda. I don't (inaudible) to make sure that we're  
6 in compliance. You know, if - we work incredibly hard to  
7 make sure that our staff are trained and qualified, you know,  
8 and to provide (inaudible) and supports, and provide patient  
9 care. We do have a 24/7, you know, on-call line for our  
10 patients. You know, we have discomfort following surgery.  
11 And my background clinical by nature. I'm a physical  
12 therapist by nature. I practiced over 20 years, um, you  
13 know, until I came over, and it was part of Kinex, but, you  
14 know, this has been horrifying for me. Like, I don't want to  
15 be in this position ever again. Um, I take it incredibly  
16 seriously and we will make sure that we do a full review in  
17 every state that we're in, that we're compliant, um, and I  
18 can guarantee you in Nevada that we will be very aware of our  
19 requirements, and this won't happen again.

20 MS. DOVE: If I could just add (inaudible)a  
21 very long unblemished history of doing - doing (inaudible)  
22 Nevada in conjunction with the (inaudible) past whether  
23 licensing was at issues. Unfortunately, COVID - COVID is  
24 undeniably a part of that delay. And so, while it certainly  
25 can't be to blame for the licensing issue as a whole, I think



1 it can be (inaudible) the duration of the problem was, um,  
2 with attributable in parts that, um, so I think that a long  
3 history of positive experience with no disciplinary action  
4 and no blemishes on their record, um, until they tried to  
5 navigate and transition where they did make mistakes.

6 FEMALE 1: I'm sorry. I accidentally unmute -  
7 uh, muted. (laughter) I apologize for that. Um.

8 MALE 2: Get ready for the next one, sorry.

9 MS. DOVE: (inaudible) probably. Um,  
10 (inaudible)

11 MALE 3: (inaudible) no just the end. We  
12 heard that they have a long history of operating un- with  
13 Gable.

14 MS. DOVE: (inaudible)

15 MALE 3: Well, I'll just say my recollection  
16 of it, which she gave her recollection of it. We got a  
17 request for a temporary license in January, uh, through  
18 email, and, uh, the administrator, uh, form was never  
19 completed to the point where it could the end (inaudible)  
20 the, uh, again, not discounting what you said, but that's my  
21 recollection of what happened with your application. So, um,  
22 you can dispute that if you choose.

23 FEMALE 3: I think, um, even at this point in  
24 time when I go through the application, I don't think it's  
25 complete, and so that was one of the question that I do have

1 for Kinex is that there's a couple, uh, forms that are  
2 (inaudible) affidavits, uh, that need to be notarized, and  
3 these were not properly notarized. So, I guess the Board  
4 staff, um, I imagine that is, to me, just an incomplete  
5 application.

6 FEMALE 1: (inaudible)

7 FEMALE 3: Um, Page 1764, 1775, 1785.

8 (pause)

9 (background)

10 FEMALE 1: Yeah, it would need the seal, um, to  
11 show that it was notarized.

12 MALE 3: Do you - do you have the application  
13 in front of you?

14 FEMALE 1: (inaudible)

15 MALE 3: Page 9 of the application and there  
16 may be a photocopy issued, but normally the seals would come  
17 through.

18 MS. DOVE: Um, we mailed in the original hard  
19 copy of that application. Um, I'm trying to look and see  
20 when that was dated.

21 MR. BUCKHOLDT: I remember completing it with our  
22 notary, Ms. Long.

23 MS. WILHELM: Exactly.

24 FEMALE 1: And we have the application here.

25 MALE 3: We - we have it - I just - your -

1 your notary may have not put the seal on it. If you're  
2 looking at Page 9 of the application.

3 (pause)

4 (background)

5 MS. DOVE: Yeah, it's one of the old seals that  
6 makes the imprint, versus the stamp seal.

7 MALE 3: We understand.

8 (pause)

9 (background)

10 FEMALE 1: Okay we do. Yes, it is - it's  
11 imprinted, yes.

12 MALE 3: It is stamped.

13 (pause)

14 (background)

15 FEMALE 4: And then the change is to Ms.  
16 Sorenson who's work history. Could you, uh, walk us through  
17 those changes?

18 MS. DOVE: Um, sure. (inaudible) I wasn't at  
19 the March meeting, but she was initially listed as being a  
20 distributor as (inaudible) she has not been an employee of  
21 Gable Distributors. She has been an employee of Kinex;  
22 however, because there was overwhelming occupancy at that  
23 location given the history of their - Kinex's partnership  
24 with Gable Distributors and the fact that Gable Distributors  
25 was actually (inaudible). My understanding and Ms. Sorenson



1 can state to it, it is an honest mistake as to (inaudible)  
2 during that period, but she has been an employed by  
3 (inaudible) Kinex (inaudible) orthopedics (inaudible) in  
4 2011, and then, Kinex acquired (inaudible) Orthopedics. And  
5 so, her employment changed, though she didn't actually change  
6 (inaudible) company other than by virtue of the acquisition  
7 and then moved to Las Vegas to continue to work for Kinex at  
8 what was formerly the Gable Distributor's location. And so,  
9 that was corrected in the amended application that was  
10 provided.

11 (pause)

12 (background)

13 FEMALE 3: Okay. And I think Mr. Buckholdt  
14 touched upon this earlier, but if you wouldn't mind, just  
15 refreshing our memories in terms of the products and the  
16 patients you serve here in Nevada and why it's important for  
17 Kinex to be in that.

18 MR. BUCKHOLDT: Sure. So, the best way I can  
19 explain it, we're a specialty orthopedic DNE provider. So, I  
20 think when most people think about DNE, they think about  
21 walkers, canes, crutches, and so forth. And we're providing  
22 post-operative rehab products for patients following  
23 orthopedic surgery. So, products would include continuous  
24 passive motion devices, bracing and supports, DDT  
25 prophylactics, mechanically through compression, (inaudible)

1 and products like that. (inaudible) so, most of the  
2 extremities and spinal. So, you know, obviously bracing for  
3 stabilization following surgery, you know, cold therapy and  
4 CPM for range of motion, uh, you know, swallowing pain  
5 control.

6 FEMALE 4: Ms. Sorenson, since you will be the  
7 (inaudible) administrator, what kind of experience do you  
8 have with those products?

9 (pause)

10 (background)

11 (laughter)

12 (background)

13 MS. SORENSON: (inaudible)

14 MALE 3: Oh, there we go. One more time.

15 FEMALE 1: Ms. Sorenson?

16 (pause)

17 (background)

18 FEMALE 1: Ms. Sorenson, you're also dialed in,  
19 I see. Um, I'm trying to unmute your phone. So, 1885 is the  
20 last four, if I'm correct. I've unmuted, you have to unmute  
21 your phone, as well, and you're unmuted now, I believe. Can  
22 you speak so we can hear you?

23 (pause)

24 (background)

25 FEMALE 1: Your unmuted, so, can you try

1 speaking into your phone so we can see if we can hear you?

2 (pause)

3 (background)

4 FEMALE 1: She muted herself again, so.

5 (pause)

6 (background)

7 FEMALE 1: Ms. Sorenson, it looks like you're  
8 unmuted. Can you speak so if we see if we can hear you?

9 (pause)

10 (background)

11 FEMALE 1: Perhaps dial \*6 on her phone.

12 (background) Okay. I think we can hear you now. Hello? Ms.  
13 Sorenson, can you speak into your phone? She's unmuted, um,  
14 Ms. Sorenson, your phone is unmuted, um.

15 MALE 3: Okay. may I suggest that, uh, we  
16 have - do we have her phone number that I can call her and  
17 maybe just move onto the next one and I'll explain and just  
18 hold onto everybody, and I'll get her to where I can talk to  
19 her and ---

20 FEMALE 3: (inaudible)

21 MALE 3: No, we have it. I'm going to call  
22 her. I think she's just having a technical difficulty.  
23 We'll just take one more item, and we'll come right back, you  
24 guys and we'll finish this up.

25 MS. WILHELM: We'll appreciate that. Thank you.



1 MALE 3: So, everybody just hold tight.  
2 [END OF RECORDING]  
3 [END OF TRANSCRIPT]  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

T R A N S C R I P T I O N I S T ' S C E R T I F I C A T E

I, Jennifer G. Scott, Transcriptionist,  
do hereby certify that this transcript  
is a true and accurate record of the  
electronically recorded proceedings,  
transcribed under my direction  
this 14th day of February, 2022.



---

JENNIFER G. SCOTT

**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021**

**Index: \$5,000.00..acknowledge**

	15th	10:23	15:19	
\$		17:17	16:4,11	6
\$5,000.00	16th	6:4	18:4,15,	6 28:11
5:9		8:2 15:6,	20,23	669-900-6833
		25	19:12,14	4:2
(	1764	24:7	21:8,13	
(inaudible) a			23:11,15,	7
22:20	1775	24:7	23 24:7,	
	1785	24:7	12,15,25	7th 5:12
			25:7,12	16:17
1	1885	4:6	26:13	
		27:19	27:14	8
1 3:4,10,			28:15,20,	
19,23 4:7,	2		21 29:1	8th 5:8
8,9,10,15,	2 10:15		30 6:20	7:18,23,24
19,22,24	11:19		16:2	15:24
9:16 13:22	12:15,19,		30th 18:3	17:16
23:6 24:6,	22 13:3,5,		35 6:25	
10,14,24	17 23:8		14:19	9
25:10			16:25 22:4	9 3:7 24:15
27:15,18,	20 22:12			25:2
25 28:4,7,	2011 26:4		4	9th 5:9
11	2019 10:24			7:18
1- 4:1	11:4		4 4:6	
1-669 4:1	2020 10:3,		18:14,16,	A
10 10:18	19		21 19:6,	
14:18	2021 5:8		13,15	absolutely
10569 4:21	24/7 22:9		21:19	13:19 22:1
1099 10:24	25th 5:10		25:15 27:6	accidentally
12:9 20:1	16:12			23:6
10th 5:6			5	accurate
8:3 11:20	3		5886256671	5:24
17:20			4:4	acknowledge
13th 8:2	3 7:16 9:10			9:19 10:7
15 3:4	13:4,23			
	14:4,9			



**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021**

**Index: acknowledged..board**

<b>acknowledged</b> 6:7	<b>amended</b> 5:24 26:9	7:18 16:17	13:24 16:16
<b>acquired</b> 26:4	<b>and-desist</b> 16:15	<b>area</b> 12:7 17:6	17:11 28:23
<b>acquisition</b> 26:6	<b>answering</b> 5:16	<b>areas</b> 3:3 <b>arisen</b> 6:2	<b>background</b> 3:9,16
<b>action</b> 14:1, 11 15:12, 16 23:3	<b>anyone's</b> 17:11	<b>arrangement</b> 20:1,4	10:14 11:5,17
<b>activity</b> 11:22	<b>anytime</b> 8:16	<b>arrangements</b> 18:17	12:14 13:21 16:7
<b>add</b> 5:14 20:11 22:20	<b>apologize</b> 23:7	<b>assumption</b> 17:3	21:18 22:11 24:9
<b>added</b> 21:6	<b>apologized</b> 14:25	<b>assurances</b> 21:21	25:4,9,14 26:12
<b>address</b> 6:2, 8 7:12 8:7	<b>appeared</b> 5:1,13	<b>attempt</b> 17:10	27:10,12, 17,24
<b>administrator</b> 5:4 23:18 27:7	<b>appears</b> 10:21	<b>attempting</b> 6:15 20:10	28:3,6,10, 12
<b>advice</b> 14:21	<b>application</b> 5:1,2,22, 24 10:2	<b>attorney</b> 4:17,18,20 8:18 14:1	<b>based</b> 4:21 <b>BEGS</b> 3:17
<b>affidavits</b> 24:2	11:9 17:24	<b>attributable</b> 23:2	4:5,20,23 7:22
<b>afoul</b> 7:10	20:13	<b>audio</b> 3:2,20	<b>billing</b> 11:25 13:7
<b>agenda</b> 3:4 20:14,16, 19 21:5 22:5	23:21,24 24:5,12, 15,19,24	<b>average</b> 13:10	<b>blame</b> 22:25
<b>agreements</b> 13:11	25:2 26:9	<b>avoid</b> 21:20	<b>blemishes</b> 23:4
<b>ahead</b> 4:11	<b>applications</b> 9:12	<b>aware</b> 17:8 20:10 22:18	<b>board</b> 5:2,5, 6,17,19
<b>alarm</b> 18:7	<b>applied</b> 16:22		6:10 7:9, 14,15 8:14
	<b>appropriately</b> 10:4	<b>B</b>	9:10,18, 22,23
	<b>April</b> 5:9,12	<b>back</b> 7:20	10:23 14:10,23 16:12

## NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC

Board Meeting on 04/01/2021

Index: Board's..confirmed

17:23 19:8	cancelled	Circling	company 3:5
20:7 21:21	20:18	13:24	4:25 5:8
24:3	candid 6:9	clarify	6:19 8:23
Board's 21:5	candidly 7:4	17:14	12:23,25
bothers	15:17	clear 3:2	26:6
19:17,20	canes 26:21	18:13,23	complete
bracing	capacity	clears 8:9	23:25
26:24 27:2	12:9 20:6	Clerk 9:16	completed
Buckholdt	care 18:24	clinical	23:19
3:14 6:8	19:1 22:9	22:11	completing
7:23 8:5	carry 6:24	close 15:10	24:21
11:6 12:3,	cease- 16:14	16:4,5	compliance
6,17,21,24	cease-and-	code 4:3	8:12 15:8
13:9,19,23	5:7 7:17	cold 27:3	17:7 22:2,
14:3,8,14	cease-and-	combination	6
17:3	desist 5:11	7:6,8	compliant
19:21,25	6:3 8:11	comment	6:19 22:17
21:12 22:1	13:25	20:12	comply 15:13
24:21	15:6,9,20	communicate	21:6
26:13,18	16:20	8:13	comprehend
Buckholt	ceased 5:13	communicated	16:21,25
4:11,13,17	certified	9:21 15:9	compression
7:11 8:9	17:16	communication	26:25
9:15	chain 8:14	6:9 10:5	concern 9:14
business	change 17:15	12:25 13:1	concerned
6:20 11:3	20:7 25:15	15:8 17:4	9:5
12:8	26:5	20:7	concerns
businesses	changed 26:5	communications	18:18
11:12	channel 15:1	15:7	confirm 16:9
<hr/> c <hr/>	channels	companies	confirmations
call 28:16,	17:13	12:10,15,	20:17
21	choose 23:22	16,20 13:6	confirmed
callers 3:11			10:22

**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021    Index: confirming..discontinued**

<b>confirming</b> 11:3	<b>continues</b> 13:14	<b>current</b> 7:5 10:7	<b>delivery</b> 11:21
<b>conformed</b> 5:25	<b>continuous</b> 26:23	<hr/> D <hr/>	<b>desist</b> 5:8 7:18
<b>confusing</b> 13:4 15:19	<b>contracted</b> 8:6 13:2	<b>daily</b> 6:11 <b>date</b> 6:3 8:10 11:21 15:4 16:18	<b>devices</b> 26:24 <b>dial</b> 3:24 28:11
<b>confusion</b> 17:21	<b>contracts</b> 12:10	<b>dated</b> 7:24 15:24 17:16 24:20	<b>dialed</b> 4:5 27:18
<b>conjunction</b> 22:22	<b>control</b> 27:5 <b>cooperate</b> 15:13	<b>dates</b> 10:16 11:6	<b>dialogue</b> 13:16 17:5 20:9
<b>constant</b> 11:10 17:4	<b>copy</b> 24:19	<b>day</b> 17:21	<b>differently</b> 9:22
<b>consult</b> 8:18 14:20	<b>correct</b> 7:2 11:8 14:8 27:20	<b>days</b> 8:19 16:1,2 17:23	<b>difficult</b> 3:3
<b>consultant</b> 20:5	<b>corrected</b> 26:9	<b>DDT</b> 26:24	<b>difficulty</b> 28:22
<b>contact</b> 7:14 11:10 14:5,10 19:7,16	<b>corrective</b> 15:16	<b>deal</b> 18:19	<b>digits</b> 4:6
<b>contacted</b> 7:9 9:22 14:1 18:14,15, 16 19:3,7	<b>could've</b> 18:17 <b>counsel</b> 3:18 8:17,20 9:7 15:25 16:11	<b>dealing</b> 19:7,9 <b>decades</b> 6:22 <b>decease</b> 15:5	<b>diligently</b> 6:16 <b>directed</b> 5:24
<b>contested</b> 10:9	<b>counties</b> 20:2	<b>December</b> 20:16,18	<b>directly</b> 20:24
<b>continue</b> 10:13 14:6 26:7	<b>couple</b> 24:1 <b>COVID</b> 22:23	<b>decided</b> 6:14 14:5 <b>decipher</b> 3:3	<b>disciplinary</b> 23:3 <b>discomfort</b> 22:10
<b>continued</b> 7:17 10:3 16:22 17:8	<b>CPM</b> 27:4 <b>crutches</b> 26:21	<b>delay</b> 22:24 <b>delivered</b> 7:25 9:3	<b>discontinued</b> 16:17

## NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC

Board Meeting on 04/01/2021

Index: discounting..find

<b>discounting</b>	<b>Dove</b> 11:8	<b>employees</b>	8:25
23:20	12:3 15:2	10:18 11:2	
<b>discovered</b>	16:13	<b>employment</b>	<b>F</b>
5:7	17:14	5:21 26:5	
<b>discuss</b>	20:11	<b>end</b> 23:11,	<b>facility</b>
14:11	21:11	19 29:2,3	10:17
<b>dispute</b>	22:20	<b>entity</b> 13:13	<b>fact</b> 16:19
23:22	23:9,14	<b>equipment</b>	25:24
<b>distribute</b>	24:18	9:6	<b>families</b>
6:25	25:5,18	<b>error</b> 7:1,4	9:25
<b>distributor</b>	<b>dry</b> 8:7	9:20 21:22	<b>February</b>
6:11,12	<b>due</b> 11:25	<b>evening</b>	10:24 11:4
11:2 12:1	<b>duly</b> 4:14	15:11	<b>felt</b> 18:22
20:4 25:20	<b>duration</b>	<b>events</b> 5:18	<b>FEMALE</b> 3:4,
<b>Distributor's</b>	23:1	<b>exact</b> 11:6	10,19 4:8,
6:14 26:8	<b>E</b>	15:4	10,15,19,
<b>distributors</b>	<b>earlier</b>	<b>excuse</b> 3:5	24 7:16
6:11,23	19:24	<b>exist</b> 13:14	9:10 13:22
10:24	26:14	<b>expecting</b>	16:11
11:23 12:7	<b>effort</b> 21:9	13:7	21:19
17:12	<b>efforts</b> 7:9,	<b>experience</b>	23:6,23
25:21,24	13 8:13	23:3 27:7	24:6,7,10,
<b>DME</b> 8:24	21:4	<b>experienced</b>	14,24
<b>DNE</b> 6:21	<b>em</b> 19:3	14:16,18	25:10,15
7:5,7	<b>email</b> 16:9	<b>explain</b> 12:1	26:13
26:19,20	23:18	26:19	27:6,15,
<b>documentation</b>	<b>emails</b> 21:2	28:17	18,25
12:17	<b>employed</b>	<b>explanation</b>	28:4,7,11,
<b>Dodge</b> 19:22	26:2	13:24	20
<b>door</b> 16:5	<b>employee</b>	<b>extremities</b>	<b>File</b> 4:21
18:3	10:19,20	27:2	<b>fill</b> 14:6
<b>doors</b> 15:10	25:20,21	<b>extremity</b>	<b>finally</b> 5:12
17:18,25			<b>find</b> 8:20
			14:24
			19:17



**Index: fine..inaudible**

**800-333-2082**

**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021**

**Index: include..license**

13:2,10,	initially		Las 4:17,21
11,22	25:19	J	26:7
14:4,21	inspected	January	laughter
15:2,3,6,	15:21	23:17	23:7 27:11
14,15,17,	inspection	Joe 5:6	Leanna 17:7
18,23	8:5 10:17	July 10:19	Leanne 8:11
16:13	inspections		lease 10:25
17:14	16:19	K	leave 18:7
18:2,8,14,	inspector	Ken 5:10,12	legal 21:15
25 19:12	5:6 16:16	kind 27:7	letter 6:4,7
20:1,13,	17:21,23	Kinex 3:5,	7:24 8:4,
14,17,18,	inspectors	11,12 4:25	16,17 9:17
21 21:1,2,	7:19	6:5,11,15,	10:22
5,11,12,25	insurance	18 7:11,17	13:25
22:5,8,21,	12:10,15,	8:3 9:12,	14:12
22 23:1,9,	16,19,23,	20 10:11,	15:24
10,11,14,	25 13:6	19,20,24,	16:2,15,20
19 24:2,6,	internally	25 11:2,3,	17:16,19,
14 25:18,	9:7	24 14:17	20,22,25
20,25	interruptions	15:10,24	19:10,11,
26:1,3,4,	6:17	20:8,13	13,15,18
6,25 27:1,	interviewed	22:13 24:1	letterhead
7,13 28:20	10:18	25:21	12:1
include	investigator	26:3,4,7,	license
26:23	5:10,12	17	6:16,21
incomplete	issue 22:25	Kinex's 7:13	7:5,7
24:4	issued 24:16	25:23	9:13,21,25
incredibly	issues 22:23	knowing	10:7 12:11
17:9 22:6,	item 3:4	16:23	13:5 18:7
15	28:23	L	19:5,22,23
information			20:8,12,
10:22			23,25
informed			21:3,4,9,
9:25 20:19			10 23:17
initial			
19:25			

**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021**

**Index: licensed..muted**

<b>licensed</b>		28:15, 21	<b>members</b>
4:20 6:12	<b>M</b>	29:1	11:24
7:10, 14			
10:1, 4	<b>Madam</b> 4:24	<b>malicious</b>	<b>memories</b>
16:25	9:16 10:15	21:22	26:15
	<b>made</b> 5:5	<b>manner</b> 19:4	<b>met</b> 9:6
<b>licenses</b>	7:14 8:13	<b>March</b> 5:6, 8,	<b>might've</b>
6:24	18:17 21:8	10, 20 6:3,	7:25 8:2
<b>licensing</b>	<b>mailed</b> 24:18	4 7:18, 23,	<b>Mike</b> 3:14
22:23, 25	<b>make</b> 21:4,	24 8:2, 3	16:8
<b>licensure</b>	15, 19	10:17, 23	
11:14	22:4, 5, 7,	11:20	<b>mind</b> 19:19
16:22 17:2	16 23:5	15:6, 24, 25	26:14
21:6 22:3	<b>makes</b> 25:6	16:9, 12	<b>mispronouncing</b>
<b>listed</b> 25:19	<b>making</b> 3:2	17:16, 17,	20:21
<b>listen</b> 18:17	18:9 19:19	20 18:3	<b>Missy</b> 15:11
<b>local</b> 12:10,	21:14	20:20	<b>mistake</b> 26:1
12	<b>MALE</b> 3:23	25:19	
<b>locally</b>	4:7, 9, 22	<b>Mark</b> 11:10	<b>mistakes</b>
14:15	9:16 10:15	<b>materials</b>	23:5
	11:19	5:19	<b>misunderstood</b>
<b>location</b>	12:15, 19,	<b>matter</b> 16:19	7:5
6:6, 21 7:8	22 13:3, 4,	<b>mechanically</b>	<b>moment</b> 16:10
8:1 10:21	5, 17, 23	26:25	<b>month</b> 17:7
11:1, 4, 9,	14:4, 9	<b>Medical</b> 3:5	<b>motion</b> 26:24
12, 14, 15	15:19 16:4	4:25	27:4
12:2 15:10	18:4, 14,	<b>Medicare</b>	<b>move</b> 11:16
18:3 25:23	15, 16, 20,	6:24	28:17
26:8	21, 23	<b>meet</b> 17:6	<b>moved</b> 26:7
<b>long</b> 9:24	19:6, 12,	<b>meeting</b> 4:3	<b>moving</b> 21:20
12:7	13, 14, 15	5:2, 21, 25	<b>muted</b> 23:7
13:13, 15	21:8, 13	6:1 16:3	28:4
22:21	23:8, 11, 15	17:24 19:8	
23:2, 12	24:12, 15,	20:15, 18	
24:22	25 25:7, 12	25:19	
<b>Lyn</b> 11:6	27:14		

**Index: nature..pen**

**800-333-2082**



**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021**

**Index: people..ready**

<b>people</b> 13:7	<b>place</b> 11:22	<b>problem</b> 23:1	<b>puts</b> 9:13
19:16			
26:20	<b>point</b> 8:16	<b>proceed</b> 9:8	
	15:7 17:22		<b>Q</b>
<b>period</b> 16:23	21:14	<b>process</b>	
20:20 26:2	23:19,23	6:10,15,17	<b>qualified</b>
		11:9 17:24	22:7
<b>permanently</b>	<b>position</b> 6:3	<b>products</b>	<b>question</b>
11:13	22:15	6:25 8:24	4:17 10:16
<b>permitted</b>	<b>positive</b>	26:15,22,	11:19
7:6	6:23 23:3	23 27:1,8	13:23
<b>person</b> 3:25	<b>possibility</b>	<b>progress</b>	23:25
12:4	20:22	17:8	<b>questionable</b>
<b>personally</b>	<b>possibly</b>	<b>prompted</b> 4:3	5:3
14:14,25	11:25	<b>properly</b>	<b>questions</b>
22:4	<b>post-operative</b>	24:3	5:16,21,23
<b>perspective</b>	8:24 26:22	<b>prophylactics</b>	6:2 7:12,
18:5	<b>potentially</b>	26:25	13 15:18
<b>Pharmacy</b>	18:10 19:3	<b>proposed</b> 5:4	<b>quick</b> 10:16
10:23	<b>practiced</b>	<b>proppe</b> 17:13	13:9
14:10,23	22:12	<b>provide</b> 5:18	<b>R</b>
<b>phone</b> 3:21,	<b>prefer</b>	8:24 10:13	<b>raise</b> 3:6
23 4:6	13:13,15	13:8,16	4:12
27:19,21	<b>prescribed</b>	22:8	<b>range</b> 27:4
28:1,11,	9:2,6	<b>provided</b>	<b>re-</b> 6:4
13,14,16	<b>president</b>	9:18 26:10	<b>reach</b> 8:19
<b>phonetic</b>	4:24 7:11	<b>provider</b>	9:1 14:20,
11:7	10:15	13:2 26:19	25 15:3
<b>photocopy</b>	14:17	<b>providing</b>	<b>reached</b> 8:11
24:16	<b>press</b> 3:7	9:6 12:23	14:15
<b>physical</b>	<b>previously</b>	20:2 26:21	<b>read</b> 3:25
22:11	5:1	<b>public</b> 7:3	<b>ready</b> 11:15
<b>physicians</b>	<b>prior</b> 5:22	<b>put</b> 21:5	23:8
8:7 9:2	6:10 17:23	25:1	
<b>piece</b> 4:1			

**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021**

**Index: real..situations**

<b>real</b> 13:9	<b>regulatory</b>	<b>rescheduled</b>	<b>seal</b> 24:10
<b>reasons</b> 5:17	6:25	20:20	25:1,6
12:1	<b>rehab</b> 26:22	<b>responded</b>	<b>seals</b> 24:16
<b>reassurances</b>	<b>relationship</b>	20:24	25:5
21:24	10:25	<b>response</b>	<b>secondary</b>
<b>recall</b> 8:10	12:18	5:18 21:3	8:3
15:4	13:1,14	<b>restate</b> 5:16	<b>secure</b> 13:10
<b>receipt</b>	<b>relocated</b>	<b>result</b> 7:4	<b>seek</b> 8:21
17:19,25	10:2	<b>resulted</b>	<b>seeking</b>
<b>receive</b> 8:17	<b>rely</b> 22:2	17:5	15:18
21:21	<b>remaining</b>	<b>retained</b>	<b>separate</b>
<b>received</b> 6:4	7:12	15:3,25	6:14 12:8
8:1,3,11,	<b>remember</b>	<b>review</b> 9:11,	<b>separating</b>
16 15:5,25	24:21	19 22:16	9:23
17:17,20,	<b>report</b>	<b>reviewed</b>	<b>seriousness</b>
22	12:16,19	11:21	8:19
<b>receiving</b>	<b>reported</b>	<b>risk</b> 9:14	<b>serve</b> 6:8
16:2	12:22	<b>risks</b> 7:3	26:16
<b>recently</b>	<b>represent</b>	9:14 18:9	<b>served</b> 5:8
6:13	16:12	<b>running</b> 7:10	<b>service</b>
<b>recollection</b>	<b>representation</b>	<b>runs</b> 12:8	12:23 13:8
23:15,16,	<b>s</b> 5:5		20:2,6
21	<b>representative</b>	<b>s</b>	<b>services</b>
<b>record</b> 4:22,	5:14 8:20	<b>safely</b> 21:25	10:13
25 16:11	<b>representative</b>	<b>safety</b> 7:4	18:11
23:4	<b>s</b> 3:6	9:5,8,11	<b>should've</b>
<b>RECORDING</b>	<b>reputable</b>	10:11	14:22
29:2	6:19	<b>sales</b> 20:2,5	<b>show</b> 24:11
<b>refreshing</b>	<b>request</b> 5:3	<b>Sandra</b> 3:19	<b>site</b> 5:6,10
26:15	20:8 23:17	5:4	16:14
<b>regard</b> 21:6	<b>requirements</b>	<b>scope</b> 7:5	<b>situations</b>
<b>regulations</b>	22:3,19		21:20
7:11 10:10			

**NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC**

**Board Meeting on 04/01/2021**

**Index: slowly..time**

<b>slowly</b> 3:25	<b>staff's</b> 18:4	12:12,18	25 21:3,4,
<b>Sorenson</b>	<b>stamp</b> 25:6	13:1	6,9,10
4:12,13	<b>stamped</b>	<b>submitted</b>	23:17
5:4 11:20	25:12	6:7 10:2	<b>terminated</b>
12:4	<b>standing</b>	20:13	20:3
25:16,25	22:5	<b>suggest</b>	<b>termination</b>
27:6,13,	<b>start</b> 17:12	28:15	20:4
15,18	<b>started</b>	<b>supports</b>	<b>terms</b> 26:15
28:7,13,14	6:10,15	22:8 26:24	<b>testified</b>
<b>Sorenson's</b>	11:9	<b>surgery</b> 9:3	4:14
5:21	<b>state</b> 5:22	22:10	<b>testimony</b>
<b>sought</b> 6:13	6:21 7:7	26:23 27:3	5:25
<b>speak</b> 7:15	8:15 21:16	<b>swallowing</b>	<b>therapist</b>
8:5 12:5	22:3,17	27:4	22:12
16:13	26:1	<b>swear</b> 4:11	<b>therapy</b> 27:3
20:23	<b>stated</b>	<b>sworn</b> 4:14	<b>thing</b> 7:16
27:22	10:20,23		8:23 15:19
28:8,13	19:22	<b>T</b>	<b>things</b> 18:5
<b>speaker</b> 3:3	<b>states</b> 6:25	<b>tabled</b> 5:2	<b>thinking</b>
<b>speaking</b>	14:19	<b>taking</b> 11:22	10:4
28:1	16:25 22:4	14:12	<b>thought</b> 20:9
<b>specialty</b>	<b>status</b> 8:14	15:12	<b>throat</b> 8:9
26:19	<b>stayed</b> 6:9	<b>talk</b> 28:18	<b>tickets</b>
<b>specifically</b>	20:4	<b>talked</b> 9:7	11:21,23
8:24	<b>steps</b> 14:24	<b>talking</b>	<b>tied</b> 6:21
<b>spinal</b> 27:2	<b>stop</b> 9:4	21:15	7:8
<b>spoke</b> 15:6	<b>Street</b> 6:6	<b>team</b> 22:2	<b>tight</b> 29:1
<b>stabilization</b>	11:1,4	<b>technical</b>	<b>time</b> 6:17
27:3	<b>stress</b> 7:2	28:22	10:25 12:8
<b>staff</b> 11:24	13:12	<b>temporary</b>	14:16
14:10	<b>stunned</b> 8:12	18:7 19:5	16:16 18:5
19:7,18	<b>subcontractor</b>	20:12,23,	23:24
22:7 24:4			

## NEVADA STATE BOARD OF PHARMACY vs KINEX MEDICAL, LLC

Board Meeting on 04/01/2021

Index: timeframe..Zoom

27:14	21 8:4,18	virtue 26:6	worried 9:4
timeframe	9:18 10:10	visit 11:20	would've
8:22	17:1 21:8		18:8,13,
timely 7:14	25:7	W	16,18,21,
timing	understanding		24 19:2,3,
15:19,23	15:15 20:6	W-2 11:2	4
17:15	25:25	walk 25:16	writing
told 20:21	understood	walkers	20:17
touched	16:21	26:21	wrong 17:9
26:14	unique 14:19	week 16:1,8	wrongdoing
trained 22:7	unlicensed	Wilhelm 3:13	13:18
TRANSCRIPT	11:4 16:23	4:11,13	Y
29:3	unmute 3:21	5:15 7:25	
transition	23:6	8:12 9:17	year 17:4
17:12 23:5	27:19,20	10:22	19:21
transitioned	unmuted	15:23 16:8	years 6:13,
11:1	27:20,21,	20:23	20 10:12,
true 17:17	25 28:8,	24:23	21 14:18
turn 4:16	13,14	28:25	16:24
11:9 15:9	update 17:8	Wisconsin	22:12
turned 10:24	updated 22:3	6:21 7:8	
types 21:20		8:20	Z
	V	work 5:3	Zoom 3:7
U		12:9	
un- 23:12	vacated	13:12,13,	
unblemished	11:13	15 18:8	
22:21	Vegas 4:18,	22:6 25:16	
undeniably	21 26:7	26:7	
22:24	versus 13:13	worked 6:22	
understand	25:6	14:22	
5:20 7:16,	vet 9:11	working	
	video 3:20,	10:18,19,	
	22	20 13:15	
		18:10 20:5	





300 N. LaSalle Street Suite 4000  
Chicago, Illinois 60654-3406  
312.715.5000  
Fax 312.715.5155  
[www.quarles.com](http://www.quarles.com)

Writer's Direct Dial: 312-715-5139  
E-Mail: [Edward.Rickert@quarles.com](mailto:Edward.Rickert@quarles.com)

March 2, 2022

**VIA ELECTRONIC MAIL**

Mr. David Wuest  
Executive Secretary  
Nevada Board of Pharmacy  
985 Damonte Ranch Pkwy Ste 206  
Reno, NV, 89521

Re: Comments to Proposed Adoption and Amendment  
to NAC 639.718

Dear Mr. Wuest:

I am writing on behalf of Caremore Health, MedAvail Technologies Inc., and MedAvail's subsidiary, SpotRx Pharmacy, to provide comments to Proposed Adoption and Amendment to NAC 639.718. Caremore Health and MedAvail originally petitioned the Board to engage in this rulemaking in 2019, and applaud the Board for taking this step to facilitate the dispensing of medications to patients at the point of care at health systems and clinics, and at other locations throughout the state where improved access to pharmacy services is needed.

We support the proposed adoption and amendment to NAC 639.718, and thank you, board counsel, and the full board for your hard work in making these revisions, which will improve access to pharmacy services for Nevada residents.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Edward D. Rickert".

---

Edward D. Rickert

cc: Brett Kandt, Esq.  
Seema Siddiqui  
Syed Sumair Akhtar, MD, MHCDS, CareMore Health

SFY22 MONTHLY BUDGET REPORT  
NEVADA STATE BOARD OF PHARMACY  
CURRENT MONTH: Feb 22

REVENUES	APPROVED BUDGET	BUDGET AMENDMENTS	REVISED BUDGET	CURRENT MONTH REVENUE/EXPENSE	PRIOR MONTH(S) REVENUE/EXPENSE	PROJECTIONS THROUGH 6/30/2022	TOTAL REVENUE/EXPENSE SFY22	DIFFERENCE
Beginning Balance	\$ 4,267,562	\$ 125,940	\$ 4,393,502	\$ -	\$ 4,393,502	\$ -	\$ 4,393,502	\$ -
Renewal Fees	\$ 1,512,000		\$ 1,512,000	\$ 3,340	\$ 1,526,868	\$ -	\$ 1,530,208	\$ 18,208
Registration Fees	\$ 668,834		\$ 668,834	\$ 63,470	\$ 890,884	\$ 50,000	\$ 1,004,354	\$ 335,520
Recovered Costs	\$ -	\$ 15,000	\$ 15,000	\$ 1,800	\$ 31,277	\$ 16,539	\$ 49,616	\$ 34,616
CC Processing Fees	\$ -	\$ 75,000	\$ 75,000	\$ 2,018	\$ 96,396	\$ 8,072	\$ 106,486	\$ 31,486
Change MGR RPh	\$ -	\$ 7,500	\$ 7,500	\$ 1,000	\$ 5,900	\$ 3,450	\$ 10,350	\$ 2,850
Inspections	\$ -	\$ 750	\$ 750	\$ -	\$ 300	\$ 150	\$ 450	\$ (300)
Interest Income	\$ 15,000		\$ 15,000	\$ -	\$ 3,726	\$ 2,661	\$ 6,387	\$ (8,613)
Indirect Grant Income	\$ 2,670	\$ (2,670)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Late Fees	\$ 17,530		\$ 17,530	\$ 1,120	\$ 10,680	\$ 5,900	\$ 17,700	\$ 170
Unclaimed Property Refund	\$ -	\$ 28,050	\$ 28,050	\$ -	\$ 28,050	\$ -	\$ 28,050	\$ -
Total Revenues	\$ 6,483,596	\$ 249,570	\$ 6,733,166	\$ 72,748	\$ 6,987,583	\$ 86,772	\$ 7,147,103	\$ 413,937

EXPENSES								
Payroll	\$ 3,340,540		\$ 3,340,540	\$ 274,407	\$ 1,821,612	\$ 1,096,631	\$ 3,192,650	\$ (147,890)
Operating	\$ 825,000		\$ 825,000	\$ 42,799	\$ 414,458	\$ 172,677	\$ 629,935	\$ (195,065)
Equipment	\$ 30,000		\$ 30,000	\$ 5,139	\$ 8,179	\$ 16,683	\$ 30,000	\$ -
In-State Travel	\$ 110,000		\$ 110,000	\$ 1,324	\$ 39,565	\$ 20,444	\$ 61,333	\$ (48,667)
Out-of-State Travel	\$ 65,000		\$ 65,000	\$ -	\$ -	\$ 35,000	\$ 35,000	\$ (30,000)
DAG Cost	\$ 12,000		\$ 12,000	\$ 3,325	\$ 4,874	\$ 3,801	\$ 12,000	\$ -
Aid for Education	\$ 2,000		\$ 2,000	\$ -	\$ -	\$ -	\$ -	\$ (2,000)
Reserve	\$ 2,099,056	\$ 249,570	\$ 2,348,626	\$ -	\$ -	\$ -	\$ 3,186,185	\$ 837,559
Total Expenses	\$ 6,483,596	\$ 249,570	\$ 6,733,166	\$ 326,993	\$ 2,286,687	\$ 1,346,237	\$ 7,147,103	\$ 413,937
Balance	\$ -	\$ -	\$ -	\$ -	\$ 2,286,687	\$ -	\$ -	\$ -